:: CLDF ::

Home | Contact Us | Bookmark

HCC

HRS

NASH

PBC

THROMBOCYTOPENIA

Centers of Educational Expertise

Live CME Meetings Webcasts Slide Library Abstract Library

Conference Highlights

HE | Abstract Library

The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.

1.	Low-Value Levels: Ammonia Testing Does Not Improve the Outcomes of Overt Hepatic Encephalopathy
	Tapper EB^1,2, Rahimi RS³. Am J Gastroenterol. 2019 Nov 8. doi: 10.14309/ajg.0000000000000454. [Epub ahead of print]

2.	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis
	Tapper EB^1,2, Henderson JB³, Parikh ND^1,2, Ioannou GN⁴, Lok AS¹. Hepatol Commun. 2019 Sep 6;3(11):1510-1519. doi: 10.1002/hep4.1425. eCollection 2019 Nov.

3.	Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis
	Haj M¹, Rockey DC¹. Am J Gastroenterol. 2019 Oct 14. doi: 10.14309/ajg.0000000000000343. [Epub ahead of print]

4.	Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy
	Nardelli S¹, Gioia S¹, Faccioli J¹, Riggio O¹, Ridola L². World J Gastroenterol. 2019 Sep 21;25(35):5257-5265. doi: 10.3748/wjg.v25.i35.5257.

5.	Health-related quality of life in patients with compensated and decompensated liver cirrhosis
	Labenz C¹, Toenges G², Schattenberg JM¹, Nagel M¹, Huber Y¹, Marquardt JU¹, Galle PR¹, Wörns MA³. Eur J Intern Med. 2019 Sep 14. pii: S0953-6205(19)30317-6. doi: 10.1016/j.ejim.2019.09.004. [Epub ahead of print]

6.	Hepatic Encephalopathy in the Hospitalized Patient: A Review for Hospitalists
	Chela HK¹, Basra N¹, Naqvi SH¹. Mo Med. 2019 Jul-Aug;116(4):308-312.

7.	Hepatic Encephalopathy is a Strong Predictor of Early Hospital Readmission Among Cirrhosis Patients
	Sood KT¹, Wong RJ¹. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):484-490. doi: 10.1016/j.jceh.2019.01.005. Epub 2019 Jan 24.

8.	Chinese guidelines on management of hepatic encephalopathy in cirrhosis
	Xu XY¹, Ding HG², Li WG³, Jia JD⁴, Wei L⁵, Duan ZP⁶, Liu YL⁷, Ling-Hu EQ⁸, Zhuang H⁹, Hepatology CSO, Association CM. World J Gastroenterol. 2019 Sep 28;25(36):5403-5422. doi: 10.3748/wjg.v25.i36.5403.

9.	The Gastroenterologist
	Shetty A¹, Jun Yum J¹, Saab S¹. Gastroenterol Hepatol (N Y). 2019 Aug;15(8):423-430.

10.	"Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics
	Moscoso CG¹, Steer CJ^1,2. Hepat Med. 2019 Sep 2;11:109-129. doi: 10.2147/HMER.S213397. eCollection 2019.

11.	Serum and urinary metabolomics and outcomes in cirrhosis
	Bajaj JS¹, Fan S², Thacker LR³, Fagan A¹, Gavis E¹, White MB¹, Heuman DM¹, Fuchs M¹, Fiehn O². PLoS One. 2019 Sep 27;14(9):e0223061. doi: 10.1371/journal.pone.0223061. eCollection 2019.

12.	Exhaled breath analysis in hepatology: State-of-the-art and perspectives
	De Vincentis A¹, Vespasiani-Gentilucci U², Sabatini A³, Antonelli-Incalzi R², Picardi A². World J Gastroenterol. 2019 Aug 14;25(30):4043-4050. doi: 10.3748/wjg.v25.i30.4043.

13.	Predicting Heart Failure After TIPS: Still More Questions Than Answers
	Baiges A^1,2, Garcia-Pagán JC^1,2. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30948. [Epub ahead of print]

14.	Critically Ill Patients with End-Stage Liver Disease
	Crager S¹. Emerg Med Clin North Am. 2019 Aug;37(3):511-527. doi: 10.1016/j.emc.2019.03.008. Epub 2019 May 21.

15.	Aminopyrine Breath Test Predict Liver-related Events and Death in HCV-related Cirrhosis on SVR after DAA Therapy
	Petta S¹, Rini F¹, Calvaruso V¹, Cammà C¹, Ciminnisi S¹, Di Marco V¹, Giannini EG², Grimaudo S¹, Pipitone RM¹, Craxì A¹. Liver Int. 2019 Sep 11. doi: 10.1111/liv.14250. [Epub ahead of print]

16.	Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study
	Vidot H^1,2, Cvejic E³, Finegan LJ⁴, Shores EA⁵, Bowen DG^6,7,8, Strasser SI^7,8, McCaughan GW^6,7,8, Carey S⁹, Allman-Farinelli M¹⁰, Shackel NA¹¹. Nutrients. 2019 Aug 6;11(8). pii: E1810. doi: 10.3390/nu11081810.

17.	Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review & Network Meta-analysis
	Dhiman RK¹, Thumburu KK², Verma N³, Chopra M³, Rathi S³, Dutta U⁴, Singal AK⁵, Taneja S³, Duseja A³, Singh M²; Indian National Association for Study of Liver (INASL) Hepatic Encephalopathy Study Group (IHESG). Clin Gastroenterol Hepatol. 2019 Aug 30. pii: S1542-3565(19)30969-3. doi: 10.1016/j.cgh.2019.08.047. [Epub ahead of print]

18.	Post-Traumatic Stress Disorder is Associated with Altered Gut Microbiota that Modulates Cognitive Performance in Veterans with Cirrhosis
	Bajaj JS¹, Sikaroodi M², Fagan A³, Heuman DM, Gilles HC⁴, Gavis EA⁴, Fuchs M⁴, Gonzalez-Maeso J⁵, Nizam S⁶, Gillevet PM⁷, Wade JB⁵. Am J Physiol Gastrointest Liver Physiol. 2019 Aug 28. doi: 10.1152/ajpgi.00194.2019. [Epub ahead of print]

19.	Hepatic encephalopathy is reversible in the long-term after liver transplantation
	Hopp AE¹, Dirks M^1,2, Petrusch C¹, Goldbecker A^1,2, Tryc AB^1,2, Barg-Hock H³, Strassburg C⁴, Klempnauer J^2,3, Weissenborn K^1,2, Pflugrad H^1,2. Liver Transpl. 2019 Aug 22. doi: 10.1002/lt.25626. [Epub ahead of print]

20.	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice
	Bajaj JS¹, Bloom PP², Chung RT², Hassanein TI³, Padilla-Martinez M³, Kayali Z⁴, Rockey DC⁵, Sasso R⁵, Muthukumar AR⁶, Lee WM⁶, Denney WS⁷, Gavis EA¹, Anderson C⁸, Blankstein L⁸, Brennan AM⁸, Puurunen MK⁸, Lawitz E⁹. Am J Gastroenterol. 2019 Aug 21. doi: 10.14309/ajg.0000000000000384. [Epub ahead of print]

21.	Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis
	Wijarnpreecha K¹, Werlang M², Panjawatanan P³, Kroner PT², Cheungpasitporn W⁴, Lukens FJ², Pungpapong S², Ungprasert P⁵. Ann Hepatol. 2019 Jul 13. pii: S1665-2681(19)32193-3. doi: 10.1016/j.aohep.2019.06.007. [Epub ahead of print]

22.	Problematic Cannabis Use and Risk of Complications in Patients with Chronic Hepatitis C
	Rashid W¹, Patel V², Ravat V³, Madireddy S⁴, Jaladi PR⁵, Tahir M⁶, Bhimanadham NN⁷, Kuduva Rajan S⁸, Imran S⁹, Patel RS¹⁰. Cureus. 2019 Aug 12;11(8):e5373. doi: 10.7759/cureus.5373.

23.	Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis
	Horvath A^1,2, Rainer F³, Bashir M⁴, Leber B⁵, Schmerboeck B^3,6, Klymiuk I⁷, Groselj-Strele A⁸, Durdevic M⁸, Freedberg DE⁹, Abrams JA⁹, Fickert P³, Stiegler P⁵, Stadlbauer V³. Sci Rep. 2019 Aug 19;9(1):12000. doi: 10.1038/s41598-019-48352-5.

24.	Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy
	Gluud LL¹, Jeyaraj R², Morgan MY². J Clin Exp Hepatol. 2019 May-Jun;9(3):354-361. doi: 10.1016/j.jceh.2019.02.004. Epub 2019 Feb 15.

25.

Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study

Vidot H^1,2, Cvejic E³, Finegan LJ⁴, Shores EA⁵, Bowen DG^6,7,8, Strasser Nutrients. 2019 Aug 6;11(8). pii: E1810. doi: 10.3390/nu11081810.

SI^7,8, McCaughan GW^6,7,8, Carey S⁹, Allman-Farinelli M¹⁰, Shackel NA¹¹.

26.	Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial
	Bajaj JS^1,2, Salzman NH³, Acharya C^1,2, Sterling RK^1,2, White MB^1,2, Gavis EA^1,2, Fagan A^1,2, Hayward M³, Holtz ML³, Matherly S^1,2, Lee H^1,2, Osman M⁴, Siddiqui MS⁴, Fuchs M³, Puri P³, Sikaroodi M⁵, Gillevet PM⁵. Hepatology. 2019 Apr 30. doi: 10.1002/hep.30690. [Epub ahead of print]

27.	Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis
	Butterworth RF¹. Metab Brain Dis. 2019 Jul 23. doi: 10.1007/s11011-019-00463-8. [Epub ahead of print]

28.	Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis
	Campion D¹, Giovo I¹, Ponzo P¹, Saracco GM¹, Balzola F¹, Alessandria C². World J Hepatol. 2019 Jun 27;11(6):489-512. doi: 10.4254/wjh.v11.i6.489.

29.	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort
	Bajaj JS¹, O'Leary JG², Tandon P³, Wong F⁴, Kamath PS⁵, Biggins SW^6,7, Garcia-Tsao G⁸, Lai J⁹, Fallon MB^10,11, Thuluvath PJ¹², Vargas HE¹³, Maliakkal B^14,15, Subramanian RM¹⁶, Thacker LR¹, Reddy KR¹⁷.

30.	Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis
	Tapper EB^1,2, Derstine B³, Baki J⁴, Su GL^5,6. Dig Dis Sci. 2019 Jul 10. doi: 10.1007/s10620-019-05713-4. [Epub ahead of print]

31.	The efficacy and safety of rifaximin-a: a 2-year observational study of overt hepatic encephalopathy
	Oey RC¹, Buck LEM², Erler NS³, van Buuren HR², de Man RA². Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858256. doi: 10.1177/1756284819858256. eCollection 2019.

32.	Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis
	Tantai XX¹, Yang LB¹, Wei ZC¹, Xiao CL¹, Chen LR¹, Wang JH¹, Liu N². World J Gastroenterol. 2019 Jun 7;25(21):2683-2698. doi: 10.3748/wjg.v25.i21.2683.

33.	Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
	Zacharias HD¹, Zacharias AP, Gluud LL, Morgan MY. Cochrane Database Syst Rev. 2019 Jun 17;6:CD012334. doi: 10.1002/14651858.CD012334.pub2. [Epub ahead of print]

34.	Beyond Lactulose: Treatment Options for Hepatic Encephalopathy
	Said VJ¹, Garcia-Trujillo E. Gastroenterol Nurs. 2019 May/Jun;42(3):277-285. doi: 10.1097/SGA.0000000000000376.

35.	Choosing Wisely Canada-Top Five List in Hepatology: Official Position Statement of the Canadian Association for the Study of the Liver (CASL) and Choosing Wisely Canada (CWC)
	Brahmania M¹, Renner EL², Coffin CS³, Yoshida EM⁴, Wong P⁵, Zeman M⁶, Shah H⁷. Ann Hepatol. 2019 Jan - Feb;18(1):165-171. doi: 10.5604/01.3001.0012.7908.

36.	Adherence to Recommended Inpatient Hepatic Encephalopathy Workup
	Kumral D¹, Qayyum R², Roseff S³, Sterling RK¹, Siddiqui MS¹.

37.	Prognostic Role of Ammonia in Patients With Cirrhosis
	Shalimar¹, Sheikh MF², Mookerjee RP², Agarwal B^2,3, Acharya SK¹, Jalan R². Hepatology. 2019 Jan 31. doi: 10.1002/hep.30534. [Epub ahead of print]

38.	A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy
	Kumar S¹, Modi R², Bhandari BM², Sass DA¹, Rothstein KD³. Ann Hepatol. 2018 Sep - Oct;17(5):810-814. doi: 10.5604/01.3001.0012.3141.

39.	How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy
	Ridola L¹, Nardelli S², Gioia S², Riggio O². J Clin Exp Hepatol. 2019 Jan-Feb;9(1):137-145. doi: 10.1016/j.jceh.2018.02.007. Epub 2018 Mar 13.

40.	Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy
	Kircheis G¹, Lüth S². Drugs. 2019 Feb;79(Suppl 1):23-29. doi: 10.1007/s40265-018-1023-2.

41.	L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
	Butterworth RF¹, McPhail MJW². Drugs. 2019 Feb;79(Suppl 1):31-37. doi: 10.1007/s40265-018-1024-1.

42.	Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample
	Hirode G¹, Vittinghoff E², Wong RJ³. Dig Dis Sci. 2019 Mar 13. doi: 10.1007/s10620-019-05576-9. [Epub ahead of print]

43.	Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis
	Ghosh G¹, Jesudian AB². J Clin Exp Hepatol. 2019 Mar-Apr;9(2):257-267. doi: 10.1016/j.jceh.2018.08.006. Epub 2018 Aug 27.

44.	Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy
	Alsahhar JS¹, Rahimi RS. Curr Opin Gastroenterol. 2019 May;35(3):145-154. doi: 10.1097/MOG.0000000000000527.

45.	Lower 90-day Hospital Readmission Rates for Esophageal Variceal Bleeding After TIPS: A Nationwide Linked Analysis
	Rush B¹, Deol N², Teriyaki A², Sey M², Jairath V^2,3, Walley KR^1,4, Celi LA^5,6, Brahmania M². J Clin Gastroenterol. 2019 Feb 27. doi: 10.1097/MCG.0000000000001199. [Epub ahead of print]

46.	Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies
	Flud CR¹, Duarte-Rojo A². J Clin Exp Hepatol. 2019 Jan-Feb;9(1):112-116. doi: 10.1016/j.jceh.2018.04.009. Epub 2018 May 4.

47.	Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy
	Bajaj JS¹, Fagan A¹, White MB¹, Wade JB², Hylemon PB^3,4, Heuman DM¹, Fuchs M¹, John BV¹, Acharya C¹, Sikaroodi M², Gillevet PM². Am J Gastroenterol. 2019 Jan 28. doi: 10.14309/ajg.0000000000000102. [Epub ahead of print]

48.	Bile Acids in Hepatic Encephalopathy
	DeMorrow S^1,2. J Clin Exp Hepatol. 2019 Jan-Feb;9(1):117-124. doi: 10.1016/j.jceh.2018.04.011. Epub 2018 May 4.

49.	Role of Exercise in the Management of Hepatic Encephalopathy: Experience From Animal and Human Studies
	Aamann L¹, Tandon P², Bémeur C^3,4. J Clin Exp Hepatol. 2019 Jan-Feb;9(1):131-136. doi: 10.1016/j.jceh.2018.07.006. Epub 2018 Aug 10.

50.	Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies
	Flud CR¹, Duarte-Rojo A². J Clin Exp Hepatol. 2019 Jan-Feb;9(1):112-116. doi: 10.1016/j.jceh.2018.04.009. Epub 2018 May 4.

51.	Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
	Butterworth RF¹. Drugs. 2019 Jan 31. doi: 10.1007/s40265-018-1017-0. [Epub ahead of print]

52.	Pelvic Floor Dysfunction in the Female Athlete
	Louis-Charles K¹, Biggie K², Wolfinbarger A¹, Wilcox B³, Kienstra CM². Curr Sports Med Rep. 2019 Feb;18(2):49-52. doi: 10.1249/JSR.0000000000000563.

53.	Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
	Montagnese S¹, Bajaj JS². Drugs. 2019 Jan 31. doi: 10.1007/s40265-018-1019-y. [Epub ahead of print]

54.	Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles
	Weissenborn K¹. Drugs. 2019 Jan 31. doi: 10.1007/s40265-018-1018-z. [Epub ahead of print]

55.	Nationwide Estimates and Risk Factors of Hospital Readmission in Patients with Cirrhosis in the United States
	Tapper EB^1,2. Hepatology. 2019 Jan 31. doi: 10.1002/hep.30533. [Epub ahead of print]

56.	Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis
	Tapper EB^1,2. Hepatology. 2019 Jan 31. doi: 10.1002/hep.30533. [Epub ahead of print]

57.	The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability
	Formentin C¹, De Rui M¹, Zoncapè M¹, Ceccato S¹, Zarantonello L¹, Senzolo M², Burra P², Angeli P¹, Amodio P¹, Montagnese S³. J Hepatol. 2019 Jan 8. pii: S0168-8278(19)30005-4. doi: 10.1016/j.jhep.2018.12.031. [Epub ahead of print]

58.	Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multi-Center Study
	Lai JC¹, Rahimi R², Verna EC³, Kappus MR⁴, Dunn MA⁵, McAdams-DeMarco M⁶, Haugen CE⁷, Volk ML⁸, Duarte-Rojo A⁹, Ganger DR¹⁰, O'leary JG¹¹, Dodge JL¹², Ladner D¹³, Segev D⁷. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30058-7. doi: 10.1053/j.gastro.2019.01.028. [Epub ahead of print]

59.	Same- vs Different-Hospital Readmissions in Patients With Cirrhosis After Hospital Discharge
	Okafor PN¹, Nnadi AK², Okoli O³, Huang AE⁴, Nwaiwu O⁵. Am J Gastroenterol. 2019 Jan 18. doi: 10.14309/ajg.0000000000000050. [Epub ahead of print]

60.	Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients
	Romano J¹, Sims OT²,³,⁴,⁵, Richman J⁶, Guo Y⁷, Matin T⁸, Shoreibah M⁹, Kommineni V¹, Venkata K¹, Massoud OI⁹. JGH Open. 2018 Sep 19;2(6):317-321. doi: 10.1002/jgh3.12091. eCollection 2018 Dec.

61.	Superior Performance of Teaching and Transplant Hospitals in the Management of Hepatic Encephalopathy from 2007 to 2014
	Bodek D¹, Patel P¹, Ahlawat S¹, Orosz E¹, Nasereddin T¹, Pyrsopoulos N¹. J Clin Transl Hepatol. 2018 Dec 28;6(4):362-371. doi: 10.14218/JCTH.2017.00078. Epub 2018 Nov 27.

62.	Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation
	Lewis DS¹, Lee TH², Konanur M¹, Ziegler C¹, Hall MD¹, Pabon-Ramos WM¹, Suhocki PV¹, Smith TP¹, Kim CY¹, Choi SS², Ronald J³. J Vasc Interv Radiol. 2019 Jan 10. pii: S1051-0443(18)31602-6. doi: 10.1016/j.jvir.2018.10.015. [Epub ahead of print]

63.	Quality of life in patients with minimal hepatic encephalopathy
	Ridola L¹, Nardelli S², Gioia S², Riggio O². World J Gastroenterol. 2018 Dec 28;24(48):5446-5453. doi: 10.3748/wjg.v24.i48.5446.

64.	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
	Montagnese S¹, Russo FP², Amodio P³, Burra P², Gasbarrini A⁴, Loguercio C⁵, Marchesini G⁶, Merli M⁷, Ponziani FR⁴, Riggio O⁷, Scarpignato C⁸. Dig Liver Dis. 2018 Dec 12. pii: S1590-8658(18)31274-X. doi: 10.1016/j.dld.2018.11.035. [Epub ahead of print]

65.	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy
	Labenz C¹,², Toenges G³, Schattenberg JM¹,², Nagel M¹,², Sprinzl MF¹,², Nguyen-Tat M¹,², Zimmermann T¹,², Huber Y¹,², Marquardt JU¹,², Galle PR¹,², Wörns MA¹,². J Clin Gastroenterol. 2018 Nov 14. doi: 10.1097/MCG.0000000000001149. [Epub ahead of print]

66.	MHE Testing in Real World Scenario
	Lauridsen MM¹, Vilstrup H². J Clin Exp Hepatol. 2018 Dec;8(4):438-440. doi: 10.1016/j.jceh.2018.04.010. Epub 2018 May 5.

67.	Current Diagnosis and Classification of Hepatic Encephalopathy
	Amodio P¹. J Clin Exp Hepatol. 2018 Dec;8(4):432-437. doi: 10.1016/j.jceh.2018.07.001. Epub 2018 Jul 11.

68.	The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy
	Dam G¹, Aamann L¹, Vistrup H¹, Gluud LL². J Clin Exp Hepatol. 2018 Dec;8(4):448-451. doi: 10.1016/j.jceh.2018.06.004. Epub 2018 Jun 27.

69.	Diet and the Role of Food in Common Gastrointestinal Diseases
	Pearlman M¹, Akpotaire O². Med Clin North Am. 2019 Jan;103(1):101-110. doi: 10.1016/j.mcna.2018.08.008.

70.	Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
	Hudson M¹,², Schuchmann M³. Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001311. [Epub ahead of print]

71.	Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing
	Duarte-Rojo A¹, Allampati S², Thacker LR³, Flud CR¹, Patidar KR⁴, White MB⁴, Klair JS¹, Heuman DM⁴, Wade JB⁵, Gavis EA⁴, Bajaj JS⁶. Metab Brain Dis. 2018 Nov 30. doi: 10.1007/s11011-018-0350-z. [Epub ahead of print]

72.	Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review
	Gayam V¹, Mandal AK¹, Khalid M¹, Shrestha B¹, Garlapati P¹, Khalid M². J Community Hosp Intern Med Perspect. 2018 Oct 15;8(5):311-314. doi: 10.1080/20009666.2018.1514933. eCollection 2018.

73.	Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
	Sturm L¹, Bettinger D¹,², Giesler M¹, Boettler T¹, Schmidt A¹, Buettner N¹, Thimme R¹, Schultheiss M¹. United European Gastroenterol J. 2018 Nov;6(9):1380-1390. doi: 10.1177/2050640618795928. Epub 2018 Aug 15.

74.	Hepatic encephalopathy: Sometimes more portal than hepatic
	Aller MA¹, Arias N²,³, Blanco-Rivero J⁴, Arias JL³,⁵, Arias J¹. J Gastroenterol Hepatol. 2018 Oct 21. doi: 10.1111/jgh.14514. [Epub ahead of print]

75.	Frailty, Psychoactive Medications, and Cognitive Dysfunction are Associated with Poor Patient-Reported Outcomes in Cirrhosis
	Tapper EB¹, Baki J¹, Parikh ND¹, Lok AS¹. Hepatology. 2018 Nov 1. doi: 10.1002/hep.30336. [Epub ahead of print]

76.	Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review
	Ooi PH¹, Gilmour SM², Yap J², Mager DR³. Clin Nutr ESPEN. 2018 Dec;28:41-51. doi: 10.1016/j.clnesp.2018.07.012. Epub 2018 Aug 14.

77.	Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
	Butterworth RF¹, Kircheis G², Hilger N³, McPhail MJW⁴. J Clin Exp Hepatol. 2018 Sep;8(3):301-313. doi: 10.1016/j.jceh.2018.05.004. Epub 2018 May 22.

78.	Hyperammonemia in Hepatic Encephalopathy
	Jayakumar AR¹,², Norenberg MD³,⁴,⁵. J Clin Exp Hepatol. 2018 Sep;8(3):272-280. doi: 10.1016/j.jceh.2018.06.007. Epub 2018 Jun 20.

79.	Periodontal Therapy Favorably Modulates the Oral-Gut-Hepatic Axis in Cirrhosis
	Bajaj JS¹, Matin P², White MB, Fagan A³, Golob Deeb J⁴, Acharya C⁵, Dalmet SS⁶, Sikaroodi M⁷, Gillevet PM⁷, Sahingur SE⁸. Am J Physiol Gastrointest Liver Physiol. 2018 Aug 17. doi: 10.1152/ajpgi.00230.2018. [Epub ahead of print]

80.	EASL Clinical Practice Guidelines on nutrition in chronic liver disease
	Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, Plauth M, Parés A. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32177-9. doi: 10.1016/j.jhep.2018.06.024. [Epub ahead of print]

81.	Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis
	Bjerring PN¹,², Gluud LL², Larsen FS¹. J Clin Exp Hepatol. 2018 Sep;8(3):286-293. doi: 10.1016/j.jceh.2018.06.002. Epub 2018 Jun 20.

82.	Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease
	Ochoa-Sanchez R¹, Rose CF¹. J Clin Exp Hepatol. 2018 Sep;8(3):262-271. doi: 10.1016/j.jceh.2018.08.001. Epub 2018 Aug 18.

83.	Race and Gradient Difference Are Associated with Increased Risk of Hepatic EncephalopathyHospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement
	Rowley MW¹,², Choi M³, Chen S⁴,², Hirsch K⁴,², Seetharam AB⁵,². J Clin Exp Hepatol. 2018 Sep;8(3):256-261. doi: 10.1016/j.jceh.2017.12.003. Epub 2017 Dec 30.

84.	Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-? (PROSPER): an observational study among 550 patients
	Krag A¹, Schuchmann M², Sodatonou H³, Pilot J³, Whitehouse J⁴, Strasser SI⁵, Hudson M⁶. Hepatol Med Policy. 2018 Jan 8;3:4. doi: 10.1186/s41124-017-0029-9. eCollection 2018.

85.	Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
	Nardelli S¹, Gioia S¹, Ridola L¹, Farcomeni A¹,², Merli M¹, Riggio O¹. Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304. [Epub ahead of print]

86.	Rifaximin has the potential to prevent complications of cirrhosis
	Flamm SL¹, Mullen KD², Heimanson Z³, Sanyal AJ⁴. Therap Adv Gastroenterol. 2018 Sep 28;11:1756284818800307. doi: 10.1177/1756284818800307. eCollection 2018.

87.	Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy
	Flamm SL¹. Am J Med Sci. 2018 Sep;356(3):296-303. doi: 10.1016/j.amjms.2018.06.008. Epub 2018 Jun 19.

88.	Olfactory Function is Affected in Patients with Cirrhosis Depending on the Severity of Hepatic Encephalopathy
	Heiser C¹, Haller B², Sohn M³, Hofauer B¹, Knopf A², Mühling T⁴, Freiherr J⁵, Bender M⁴, Tiller M⁴, Schmidt A⁴, Schepp W⁴, Gundling F. Ann Hepatol. 2018 Aug 24;17(5):822-829. doi: 10.5604/01.3001.0012.3143.

89.	Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index
	Tapper EB¹,², Konerman M¹, Murphy S³,⁴, Sonnenday CJ⁵. Am J Transplant. 2018 Jul 18. doi: 10.1111/ajt.15020. [Epub ahead of print]

90.	Evaluation of the cost-effectiveness of rifaximin-? for the management of patients with hepatic encephalopathy in the United Kingdom
	Berni E¹, Murphy D², Whitehouse J², Conway P¹, Di Maggio P², Currie CJ¹,³, Poole C⁴. Curr Med Res Opin. 2018 Aug 13:1-8. doi: 10.1080/03007995.2018.1499506. [Epub ahead of print]

91.	Current Management of Hepatic Encephalopathy
	Acharya C¹, Bajaj JS². Am J Gastroenterol. 2018 Jul 13. doi: 10.1038/s41395-018-0179-4. [Epub ahead of print]

92.	Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
	Neff G¹, Zachry W 3rd². Pharmacoeconomics. 2018 Jul;36(7):809-822. doi: 10.1007/s40273-018-0641-6.

93.	Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
	Lee EW¹,², Saab S, Kaldas F³,⁴, Fletcher S⁵, Busuttil RW³,⁴, Durazo F³,⁶, McWilliams JP⁵, DiNorcia J 3rd³,⁴, Padia SA⁵, Kee ST⁵. Am J Gastroenterol. 2018 Aug;113(8):1187-1196. doi: 10.1038/s41395-018-0109-5. Epub 2018 Jun 14.

94.	Hepatic encephalopathy: current challenges and future prospects
	Swaminathan M¹, Ellul MA², Cross TJ¹. Hepat Med. 2018 Mar 22;10:1-11. doi: 10.2147/HMER.S118964. eCollection 2018.

95.	Why and when to measure ammonemia in cirrhosis?
	Mallet M¹, Weiss N², Thabut D¹, Rudler M³. Clin Res Hepatol Gastroenterol. 2018 Mar 15. pii: S2210-7401(18)30031-7. doi: 10.1016/j.clinre.2018.01.004. [Epub ahead of print]

96.	Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision
	Rowley MW¹,², Choi M³, Chen S⁴,², Hirsch K⁴,², Seetharam AB⁵,⁶. Cardiovasc Intervent Radiol. 2018 Jun 5. doi: 10.1007/s00270-018-1992-2. [Epub ahead of print]

97.	Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials
	Rathi S¹, Fagan A², Wade JB³, Chopra M¹, White MB², Ganapathy D², Acharya C², Dhiman RK¹, Bajaj JS². J Clin Exp Hepatol. 2018 Jun;8(2):109-115. doi: 10.1016/j.jceh.2017.11.010. Epub 2017 Dec 2.

98.	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
	Bajaj JS¹, Barbara G², DuPont HL³, Mearin F⁴, Gasbarrini A⁵, Tack J⁶. Dig Liver Dis. 2018 Aug;50(8):741-749. doi: 10.1016/j.dld.2018.04.020. Epub 2018 Apr 27.

99.	Liver-Microbiome Axis in Health and Disease
	Adolph TE¹, Grander C¹, Moschen AR1, Tilg H2.

100.	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests
	Tapper EB¹,²,³, Parikh ND¹,²,³, Waljee AK¹,²,³, Volk M⁴, Carlozzi NE⁵, Lok AS¹,². Am J Gastroenterol. 2018 Apr;113(4):529-538. doi: 10.1038/ajg.2018.6. Epub 2018 Mar 13.

101.	Considerations for the cost-effective management of hepatic encephalopathy
	Flamm SL¹. Am J Manag Care. 2018 Mar;24(4 Suppl):S51-S61.

102.	Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
	Nardelli S¹, Ridola L², Gioia S³, Riggio O³. Curr Treat Options Gastroenterol. 2018 Jun;16(2):253-259. doi: 10.1007/s11938-018-0183-1.

103.	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant
	Bajaj JS¹, Kakiyama G¹, Savidge T², Takei H³, Kassam ZA⁴, Fagan A¹, Gavis EA¹, Pandak WM¹, Nittono H³, Hylemon PB¹, Boonma P², Haag A², Heuman DM¹, Fuchs M¹, John B¹, Sikaroodi M⁵, Gillevet PM⁵. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037. [Epub ahead of print]

104.	Acute-on-Chronic Liver Failure: Getting ready for prime-time
	Bajaj JS¹, Moreau R², Kamath PS³, Vargas HE⁴, Arroyo V⁵, Reddy KR⁶, Szabo G⁷, Tandon P⁸, Olson J⁹, Karvellas C⁸, Gustot T¹⁰, Lai JC¹¹, Wong F¹². Hepatology. 2018 Apr 24. doi: 10.1002/hep.30056. [Epub ahead of print]

105.	Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
	Koretz RL¹,². Am J Gastroenterol. 2018 Jun 19. doi: 10.1038/s41395-018-0138-0. [Epub ahead of print]

106.	Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
	Lee EW¹,², Saab S, Kaldas F³,⁴, Fletcher S⁵, Busuttil RW³,⁴, Durazo F³,⁶, McWilliams JP⁵, DiNorcia J 3rd³,⁴, Padia SA⁵, Kee ST⁵. Am J Gastroenterol. 2018 Jun 14. doi: 10.1038/s41395-018-0109-5. [Epub ahead of print]

107.	Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis
	Barone M¹, Shahini E¹, Iannone A¹, Viggiani MT¹, Corvace V², Principi M¹, Di Leo A³. Dig Liver Dis. 2018 May;50(5):496-500. doi: 10.1016/j.dld.2018.01.133. Epub 2018 Jan 31.

108.	Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision
	Rowley MW¹,², Choi M³, Chen S⁴,², Hirsch K⁴,², Seetharam AB⁵,⁶. Cardiovasc Intervent Radiol. 2018 Jun 5. doi: 10.1007/s00270-018-1992-2. [Epub ahead of print]

109.	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
	Bajaj JS¹, Barbara G², DuPont HL³, Mearin F⁴, Gasbarrini A⁵, Tack J⁶. Dig Liver Dis. 2018 Apr 27. pii: S1590-8658(18)30717-5. doi: 10.1016/j.dld.2018.04.020. [Epub ahead of print]

110.	L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathyin people with cirrhosis
	Goh ET¹, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. Cochrane Database Syst Rev. 2018 May 15;5:CD012410. doi: 10.1002/14651858.CD012410.pub2.

111.	Acute-on-Chronic Liver Failure: Getting ready for prime-time
	Bajaj JS¹, Moreau R², Kamath PS³, Vargas HE⁴, Arroyo V⁵, Reddy KR⁶, Szabo G⁷, Tandon P⁸, Olson J⁹, Karvellas C⁸, Gustot T¹⁰, Lai JC¹¹, Wong F¹². Hepatology. 2018 Apr 24. doi: 10.1002/hep.30056. [Epub ahead of print]

112.	Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample
	Haj M¹, Hart M¹, Rockey DC¹. J Investig Med. 2018 May 14. pii: jim-2018-000709. doi: 10.1136/jim-2018-000709. [Epub ahead of print]

113.	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant
	Bajaj JS¹, Kakiyama G¹, Savidge T², Takei H³, Kassam ZA⁴, Fagan A¹, Gavis EA¹, Pandak WM¹, Nittono H³, Hylemon PB¹, Boonma P², Haag A², Heuman DM¹, Fuchs M¹, John B¹, Sikaroodi M⁵, Gillevet PM⁵. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037. [Epub ahead of print]

114.	Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
	Nardelli S¹, Ridola L², Gioia S³, Riggio O³. Curr Treat Options Gastroenterol. 2018 Jun;16(2):253-259. doi: 10.1007/s11938-018-0183-1.

115.	Hepatic encephalopathy: Diagnosis and management
	Amodio P¹. Liver Int. 2018 Apr 6. doi: 10.1111/liv.13752. [Epub ahead of print]

116.	Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score
	Greinert R#, Ripoll C, Zipprich A#.Z Gastroenterol. 2018 Jan 16. doi: 10.1055/s-0043-123766. [Epub ahead of print]

117.	Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy
	Gadiparthi C¹, Cholankeril G², Yoo ER³, Hu M⁴, Wong RJ⁵, Ahmed A⁶,⁷. Dig Dis Sci. 2018 Apr 2. doi: 10.1007/s10620-018-5032-5. [Epub ahead of print]

118.	Hepatic encephalopathy: current challenges and future prospects
	Swaminathan M¹, Ellul MA², Cross TJ¹. Hepat Med. 2018 Mar 22;10:1-11. doi: 10.2147/HMER.S118964. eCollection 2018.

119.	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests
	Tapper EB¹,²,³, Parikh ND¹,²,³, Waljee AK¹,²,³, Volk M⁴, Carlozzi NE⁵, Lok AS¹,². Am J Gastroenterol. 2018 Mar 13. doi: 10.1038/ajg.2018.6. [Epub ahead of print]

120.	Why and when to measure ammonemia in cirrhosis?
	Mallet M¹, Weiss N², Thabut D¹, Rudler M³. Clin Res Hepatol Gastroenterol. 2018 Mar 15. pii: S2210-7401(18)30031-7. doi: 10.1016/j.clinre.2018.01.004. [Epub ahead of print]

121.	Prevalence of restless legs syndrome in a tertiary cohort of ambulant patients with chronic liver disease
	Ma MX¹, Huang Y¹,², Adams LA¹,², Gilpin R¹, Garas G¹,², MacQuillan G¹,², Jeffrey GP¹,², Nicholas RM¹. Intern Med J. 2018 Mar;48(3):347-350. doi: 10.1111/imj.13719.

122.	Interventions to improve physical function and prevent adverse events in cirrhosis
	Trivedi HD¹, Tapper EB². Gastroenterol Rep (Oxf). 2018 Feb;6(1):13-20. doi: 10.1093/gastro/gox042. Epub 2018 Jan 10.

123.	Gut?:?liver?:?brain axis: the microbial challenge in the hepatic encephalopathy
	Mancini A¹, Campagna F², Amodio P², Tuohy KM¹. Food Funct. 2018 Feb 27. doi: 10.1039/c7fo01528c. [Epub ahead of print]

124.	The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies
	Ridola L¹, Cardinale V¹, Riggio O². Ann Gastroenterol. 2018 Mar-Apr;31(2):151-164. doi: 10.20524/aog.2018.0232. Epub 2018 Feb 1.

125.	Considerations for the cost-effective management of hepatic encephalopathy
	Flamm SL¹. Am J Manag Care. 2018 Mar;24(4 Suppl):S51-S61.

126.	Assessment of the Spectrum of Hepatic Encephalopathy: A Multi-Center Study
	Reuter B¹, Walter K², Bissonnette J³, Leise MD⁴, Lai J⁵, Tandon P⁶, Kamath PS⁴, Biggins SW², Rose CF³, Wade JB¹, Bajaj JS¹. Liver Transpl. 2018 Feb 19. doi: 10.1002/lt.25032. [Epub ahead of print]

127.	Reducing recurrent hospital admissions in patients with decompensated cirrhosis
	Aspinall RJ¹. Br J Hosp Med (Lond). 2018 Feb 2;79(2):93-96. doi: 10.12968/hmed.2018.79.2.93.

128.	Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis
	Cao Q¹, Yu CB¹, Yang SG¹, Cao HC¹, Chen P¹, Deng M¹, Li LJ². Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):9-16. doi: 10.1016/j.hbpd.2018.01.005. Epub 2018 Feb 2.

129.	Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy
	Davis BC¹, Bajaj JS¹. Alcohol Clin Exp Res. 2018 Feb 8. doi: 10.1111/acer.13605. [Epub ahead of print]

130.	Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin
	Reigadas E¹,²,³, Alcalá L¹,³,⁴, Gómez J¹, Marín M¹,²,³,⁴, Martin A¹,³, Onori R¹, Muñoz P¹,²,³,⁴, Bouza E¹,²,³,⁴. Clin Infect Dis. 2017 Oct 23. doi: 10.1093/cid/cix918. [Epub ahead of print]

131.

Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis

Schepis F¹, Vizzutti F², Garcia-Tsao G³, Marzocchi G⁴, Rega L⁵, De Maria N⁶, Di Maira T⁶, Gitto S⁶, Caporali C⁴, Colopi S⁴, De Santis M⁴, Arena U⁷, Rampoldi A⁸, Airoldi A⁹, Cannavale A¹⁰, Fanelli F¹⁰, Mosconi C¹¹, Renzulli M¹¹, Agazzi R¹², Nani R¹², Quaretti P¹³, Fiorina I¹³, Moramarco L¹³, Miraglia R¹⁴, Luca A¹⁴, Bruno R¹⁵, Fagiuoli S¹⁶, Golfieri R¹¹, Torricelli P⁴, Di Benedetto F¹⁷, Saverio Belli L⁹, Banchelli F¹⁸, Laffi G⁷, Marra F¹⁹, Villa E⁶. Clin Gastroenterol Hepatol. 2018 Jan 25. pii: S1542-3565(18)30097-1. doi: 10.1016/j.cgh.2018.01.029. [Epub ahead of print]

132.	Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans
	Burroughs TK1, Wade JB2, Ellwood MS1, Fagan A3, Heuman DM3, Fuchs M3, Bajaj JS4. Dig Dis Sci. 2018 Jan 8. doi: 10.1007/s10620-017-4894-2. [Epub ahead of print]

133.	Lactulose: A Simple Sugar in a Complex Encephalopathy
	Wijdicks EFM1. Neurocrit Care. 2018 Jan 2. doi: 10.1007/s12028-017-0494-4. [Epub ahead of print]

134.	The emergency medicine evaluation and management of the patient with cirrhosis
	Long B1, Koyfman A2. Am J Emerg Med. 2017 Dec 23. pii: S0735-6757(17)31049-5. doi: 10.1016/j.ajem.2017.12.047. [Epub ahead of print]

135.	Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study
	Weiss N1,2,3,4,5,6,7,8, Tripon S1,2,3,4,5,6,7,8, Lodey M, Guiller E, Junot H, Monneret D1,2,3,4,5,6,7,8, Mayaux J, Brisson H, Mallet M1,2,3,4,5,6,7,8, Rudler M1,2,3,4,5,6,7,8, Imbert-Bismut F1,2,3,4,5,6,7,8, Thabut D1,4; Brain-Liver Pitié-Salpêtrière Study Group (BLIPS). Fundam Clin Pharmacol. 2017 Dec 14. doi: 10.1111/fcp.12340. [Epub ahead of print]

136.	Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
	Roggeri DP1, Roggeri A1. Hepat Med. 2017 Sep 25;9:37-43. doi: 10.2147/HMER.S146438. eCollection 2017.

137.	A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis
	Tapper EB1,2, Parikh N1,2, Sengupta N3, Mellinger J1, Ratz D4, Lok AS1, Su GL1,2. Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628. [Epub ahead of print]

138.	The impact of rifaximin-? on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
	Hudson M1, Radwan A2, Di Maggio P2, Cipelli R3, Ryder SD4, Dillon JF5, Cash WJ6, Przemioslo RT7, Wright M8, Shawcross DL9, Jalan R10, Saksena S11, Allison M12, Richardson P13, Farrington E14, Aspinall RJ15. Frontline Gastroenterol. 2017 Oct;8(4):243-251. doi: 10.1136/flgastro-2016-100792. Epub 2017 Apr 7.

139.	Recent advances in hepatic encephalopathy
	Liere V#1, Sandhu G#2, DeMorrow S1,3. F1000Res. 2017 Sep 4;6:1637. doi: 10.12688/f1000research.11938.1. eCollection 2017.

140.	An educational tool for the prophylaxis of hepatic encephalopathy
	Garrido M1, Turco M1, Formentin C1, Corrias M1, De Rui M1, Montagnese S1, Amodio P1. BMJ Open Gastroenterol. 2017 Sep 11;4(1):e000161. doi: 10.1136/bmjgast-2017-000161. eCollection 2017.

141.	Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm?
	de Lorenzo-Pinto A1, García-Sánchez R2, Lorenzo-Salinas A3. Rev Esp Enferm Dig. 2017 Sep 18;109. doi: 10.17235/reed.2017.5106/2017. [Epub ahead of print]

142.	A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis
	Cook NA1, Kim JU1, Pasha Y1, Crossey MM1, Schembri AJ2,3, Harel BT2,4, Kimhofer T5, Taylor-Robinson SD1. Int J Gen Med. 2017 Sep 6;10:281-289. doi: 10.2147/IJGM.S140197. eCollection 2017.

143.	Brain Microstructural Abnormalities in Patients With Cirrhosis Without Overt Hepatic Encephalopathy: A Voxel-Based Diffusion Kurtosis Imaging Study
	Chen HJ1, Liu PF2, Chen QF2, Shi HB3. AJR Am J Roentgenol. 2017 Aug 16:1-8. doi: 10.2214/AJR.17.17827. [Epub ahead of print]

144.	Electro-Radiological Observations of Grade III/IV Hepatic EncephalopathyPatients with Seizures
	Newey CR1,2, George P3, Sarwal A4, So N5, Hantus S3,5. Neurocrit Care. 2017 Aug 8. doi: 10.1007/s12028-017-0435-2. [Epub ahead of print]

145.	Ammonia Levels and Hepatic Encephalopathy in Patients with Known Chronic Liver Disease
	Ninan J1, Feldman L2. J Hosp Med. 2017 Aug;12(8):659-661. doi: 10.12788/jhm.2794.

146.	A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis
	Tandon P1, Reddy KR2, O'Leary JG3, Garcia-Tsao G4, Abraldes JG1, Wong F5, Biggins SW6, Maliakkal B7, Fallon MB8, Subramanian RM9, Thuluvath P10, Kamath PS11, Thacker LR12, Bajaj JS12; North American Consortium for the Study of End-Stage Liver Disease. Hepatology. 2017 Jan;65(1):217-224. doi: 10.1002/hep.28900. Epub 2016 Nov 29.

147.	Optimal treatment of hepatic encephalopathy
	Allampati S1, Mullen KD. Minerva Gastroenterol Dietol. 2016 Dec;62(4):296-304. Epub 2016 Oct 20.

148.	Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis
	Liu TL1, Trogdon J2, Weinberger M3,4, Fried B5, Barritt AS 4th6. Dig Dis Sci. 2016 Nov;61(11):3335-3345. Epub 2016 Aug 1.

149.	Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study
	Jepsen P1,2, Christensen J3, Weissenborn K4, Watson H5, Vilstrup H6. BMC Gastroenterol. 2016 Jul 26;16(1):77. doi: 10.1186/s12876-016-0487-3.

150.	Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy
	Olesen SS1, Gram M2, Jackson CD3, Halliday E4, Sandberg TH2, Drewes AM5, Morgan MY4. J Hepatol. 2016 Sep;65(3):517-23. doi: 10.1016/j.jhep.2016.05.004. Epub 2016 May 13.

151.	Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients
	Thomas KL1, La AQ, Punia S, Doroudgar S, Perry PJ. Ann Clin Psychiatry. 2016 Feb;28(1):37-42.

152.	Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia
	Rahimi RS1, Rockey DC2. Semin Liver Dis. 2016 Feb;36(1):48-55. doi: 10.1055/s-0036-1571298. Epub 2016 Feb 12.

153.	A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy
	Schiff S1, Casa M1, Di Caro V1, Aprile D1, Spinelli G1, De Rui M1, Angeli P1, Amodio P1, Montagnese S1. Hepatology. 2016 May;63(5):1651-9. doi: 10.1002/hep.28477. Epub 2016 Mar 2.

154.	Techniques for Transjugular Intrahepatic Portosystemic Shunt Reduction and Occlusion
	Taylor AG1, Kolli KP2, Kerlan RK Jr2. Tech Vasc Interv Radiol. 2016 Mar;19(1):74-81. doi: 10.1053/j.tvir.2016.01.008. Epub 2016 Jan 29.

155.	Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients
	Barboza KC1, Salinas LM2, Sahebjam F2, Jesudian AB3, Weisberg IL4, Sigal SH2. Metab Brain Dis. 2016 Mar 31. [Epub ahead of print]

156.	Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt
	Nardelli S1, Gioia S1, Pasquale C1, Pentassuglio I1, Farcomeni A1,2, Merli M1, Salvatori FM1,3, Nikolli L1, Torrisi S1, Greco F1, Nicoletti V1, Riggio O1. Am J Gastroenterol. 2016 Mar 1. doi: 10.1038/ajg.2016.29. [Epub ahead of print]

157.	RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial
	Schulz C1,2, Schütte K3, Kropf S4, Schmitt FC5, Vasapolli R6, Kliegis LM7, Riegger A8, Malfertheiner P9. Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.

158.	A low-cost, user-friendly EEG recording system for the assessment of hepatic encephalopathy
	Sami S1, Mariella C1, Valeria DC1, Daniele A1, Giuseppe S1, Michele R1, Paolo A1, Piero A1, Sara M1. Hepatology. 2016 Feb 2. doi: 10.1002/hep.28477. [Epub ahead of print]

159.	The why and wherefore of hepatic encephalopathy
	Grover VP1, Tognarelli JM1, Massie N1, Crossey MM1, Cook NA1, Taylor-Robinson SD1. Int J Gen Med. 2015 Dec 16;8:381-90. doi: 10.2147/IJGM.S86854. eCollection 2015.

160.	In Patients with Cirrhosis, Driving Simulator Performance is Associated With Real-life Driving
	Lauridsen MM1, Thacker LR2, White MB1, Unser A1, Sterling RK1, Stravitz RT1, Matherly S1, Puri P1, Sanyal AJ1, Gavis EA1, Luketic V1, Siddiqui MS1, Heuman DM1, Fuchs M1, Bajaj JS3. Clin Gastroenterol Hepatol. 2015 Nov 18. pii: S1542-3565(15)01547-5. doi: 10.1016/j.cgh.2015.11.007. [Epub ahead of print]

161.	Probiotics are Helpful in Hepatic Encephalopathy: A Meta-Analysis of Randomized Trials
	Saab S1,2, Suraweera D3, Au J4, Saab E1, Alper T1, Tong MJ1,2,5. Liver Int. 2015 Nov 12. doi: 10.1111/liv.13005. [Epub ahead of print]

162.	Clinical science workshop: targeting the gut-liver-brain axis
	Patel VC1, White H1, Støy S1, Bajaj JS2, Shawcross DL3. Metab Brain Dis. 2015 Oct 8. [Epub ahead of print]

163.	Qualifying and quantifying minimal hepatic encephalopathy
	Morgan MY1, Amodio P2, Cook NA3, Jackson CD4, Kircheis G5, Lauridsen MM6, Montagnese S2, Schiff S2, Weissenborn K7. Metab Brain Dis. 2015 Sep 28. [Epub ahead of print]

164.	What is new about diet in hepatic encephalopathy
	Merli M1, Iebba V2, Giusto M3. Metab Brain Dis. 2015 Sep 29. [Epub ahead of print]

165.	Comprehensive Care of Patients with Chronic Liver Disease
	James J1, Liou IW2. Med Clin North Am. 2015 Sep;99(5):913-33. doi: 10.1016/j.mcna.2015.05.001. Epub 2015 Jul 2.

166.	MODULATION OF GABAA RECEPTORS BY NEUROSTEROIDS. A NEW CONCEPT TO IMPROVE COGNITIVE AND MOTOR ALTERATIONS IN HEPATIC ENCEPHALOPATHY
	Agusti A1, Llansola M2, Hernández-Rabaza V2, Cabrera-Pastor A2, Montoliu C1, Felipo V3. J Steroid Biochem Mol Biol. 2015 Aug 22. pii: S0960-0760(15)30052-2. doi: 10.1016/j.jsbmb.2015.08.020. [Epub ahead of print]

167.	Current diagnosis and management of post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) refractory hepatic encephalopathy
	Pereira K1, Carrion AF2, Martin P2, Vaheesan K2, Salsamendi J1, Doshi M1, Yrizarry JM1. Liver Int. 2015 Sep 1. doi: 10.1111/liv.12956. [Epub ahead of print]

168.	Resting-state functional connectivity abnormalities correlate with psychometric hepatic encephalopathy score in cirrhosis
	Chen HJ1, Jiang LF2, Sun T3, Liu J3, Chen QF4, Shi HB5. Eur J Radiol. 2015 Aug 18. pii: S0720-048X(15)30078-4. doi: 10.1016/j.ejrad.2015.08.005. [Epub ahead of print]

169.	Altered metal metabolism in patients with HCV-related cirrhosis and hepatic
	Marano M1, Vespasiani Gentilucci U, Altamura C, Siotto M, Squitti R, Bucossi S, Quintiliani L, Migliore S, Greco F, Scarciolla L, Quattrocchi CC, Picardi A, Vernieri F. Metab Brain Dis. 2015 Aug 27. [Epub ahead of print]

170.	Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients
	Jepsen P1, Watson H2, Andersen PK3, Vilstrup H4. J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470-5. doi: 10.1016/j.jhep.2015.07.007. [Epub ahead of print]

171.	New Methods of Testing and Brain Imaging in Hepatic Encephalopathy: A Review
	Edula RG1, Pyrsopoulos NT2. Clin Liver Dis. 2015 Aug;19(3):449-59. doi: 10.1016/j.cld.2015.04.001. Epub 2015 May 23.

172.	Varices and Variceal Hemorrhage in Cirrhosis. A new view of an old problem
	Garcia-Tsao G1, Bosch J2. Clin Gastroenterol Hepatol. 2015 Jul 17. pii: S1542-3565(15)00970-2. doi: 10.1016/j.cgh.2015.07.012. [Epub ahead of print]

173.	The Clinical Relevance of Minimal Hepatic Encephalopathy - A Critical Look
	Weissenborn K1. Dig Dis. 2015;33(4):555-61. doi: 10.1159/000375348. Epub 2015 Jul 6.

174.	Diagnosis of minimal hepatic encephalopathy
	Weissenborn K1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S54-9. doi: 10.1016/j.jceh.2014.06.005. Epub 2014 Jul 31.

175.	Hepatic encephalopathy and sleepiness: an interesting connection?
	Montagnese S1, Turco M1, Amodio P1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S49-53. doi: 10.1016/j.jceh.2014.06.006. Epub 2014 Jun 29.

176.	Clinical neurophysiology of hepatic encephalopathy
	Amodio P1, Montagnese S1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S60-8. doi: 10.1016/j.jceh.2014.06.007. Epub 2014 Aug 3.

177.	Minimal hepatic encephalopathy impairs quality of life
	Agrawal S1, Umapathy S1, Dhiman RK1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S42-8. doi: 10.1016/j.jceh.2014.11.006. Epub 2014 Dec 4.

178.	Detecting minimal hepatic encephalopathy in an endemic country for hepatitis B: the role of psychometrics and serum IL-6
	Tsai CF1, Chu CJ2, Huang YH2, Wang YP3, Liu PY4, Lin HC2, Lee FY2, Lu CL3. PLoS One. 2015 Jun 3;10(6):e0128437. doi: 10.1371/journal.pone.0128437. eCollection 2015.

179.	Anxiety and depression symptoms in hepatic encephalopathy: are they psychiatric or organic?
	Telles-Correia D1, João Freire M2, Mega I3, Barreiras D4, Cortez Pinto H2. Transplant Proc. 2015 May;47(4):1005-7. doi: 10.1016/j.transproceed.2015.03.011.

180.	The confusion assessment method for the intensive care unit in patients with cirrhosis
	Orman ES1, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA. Metab Brain Dis. 2015 May 7. [Epub ahead of print]

181.	Cognitive dysfunction and hepatitis C virus infection
	Solinas A1, Piras MR1, Deplano A1. World J Hepatol. 2015 May 8;7(7):922-5. doi: 10.4254/wjh.v7.i7.922.

182.	The etiology of cirrhosis is a strong determinant of brain reserve: A multi-modal MR imaging study
	Ahluwalia V1, Wade JB, Moeller FG, White MB, Unser AB, Gavis EA, Sterling RK, Stravitz RT, Sanyal AJ, Siddiqui MS, Puri P, Luketic V, Heuman DM, Fuchs M, Matherly S, Bajaj JS. Liver Transpl

183.	Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis
	Zhang Y1, Feng Y1, Cao B2, Tian Q1. Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. eCollection 2015.

184.	Covert hepatic encephalopathy: does the mini-mental state examination help?
	Corrias M1, Turco M1, Rui MD1, Gatta A1, Angeli P1, Merkel C1, Amodio P1, Schiff S1, Montagnese S1. J Clin Exp Hepatol. 2014 Jun;4(2):89-93. doi: 10.1016/j.jceh.2013.12.005. Epub 2014 Jan 24.

185.	Presentation and complications associated with cirrhosis of the liver
	Poordad FF1. Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905.

186.	Branched-chain amino acids for people with hepatic encephalopathy
	Gluud LL1, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Cochrane Database Syst Rev. 2015 Feb 25;2:CD001939. doi: 10.1002/14651858.CD001939.pub2.

187.	Impact of Physician Specialty on Quality Care for Patients Hospitalized with Decompensated Cirrhosis
	Lim N1, Lidofsky SD1. PLoS One. 2015 Apr 2;10(4):e0123490. doi: 10.1371/journal.pone.0123490.

188.	Management of patients with decompensated cirrhosis
	Harrison PM1. Clin Med. 2015 Apr;15(2):201-3. doi: 10.7861/clinmedicine.15-2-201.

189.	Salivary Microbiota Reflects Changes in Gut Microbiota in Cirrhosis with Hepatic Encephalopathy
	Bajaj JS1, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Hepatology. 2015 Mar 29. doi: 10.1002/hep.27819. [Epub ahead of print]

190.	Psychoactive Medications Increase the Risk of Falls and Fall-Related Injuries in Hospitalized Patients with Cirrhosis
	Tapper EB1, Risech-Neyman Y2, Sengupta N3. Clin Gastroenterol Hepatol. 2015 Mar 25. pii: S1542-3565(15)00305-5. doi: 10.1016/j.cgh.2015.03.019. [Epub ahead of print]

191.	Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients
	Li W1, Li N, Wang R, Li Q, Wu H. Hepatol Int. 2015 Mar 21. [Epub ahead of print]

192.	Nutrition in the management of cirrhosis and its neurological complications
	Bémeur C1, Butterworth RF2. J Clin Exp Hepatol. 2014 Jun;4(2):141-50. doi: 10.1016/j.jceh.2013.05.008. Epub 2013 Jun 11.

193.	Covert hepatic encephalopathy: does the mini-mental state examination help?
	Corrias M1, Turco M1, Rui MD1, Gatta A1, Angeli P1, Merkel C1, Amodio P1, Schiff S1, Montagnese S1. J Clin Exp Hepatol. 2014 Jun;4(2):89-93. doi: 10.1016/j.jceh.2013.12.005. Epub 2014 Jan 24.

194.	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
	Adinolfi LE1, Nevola R1, Lus G1, Restivo L1, Guerrera B1, Romano C1, Zampino R1, Rinaldi L1, Sellitto A1, Giordano M1, Marrone A1. World J Gastroenterol. 2015 Feb 28;21(8):2269-2280.

195.	Presentation and complications associated with cirrhosis of the liver
	Poordad FF1. Curr Med Res Opin. 2015 Feb 20:1-27. [Epub ahead of print]

196.	Branched-chain amino acids for people with hepatic encephalopathy
	Gluud LL1, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Cochrane Database Syst Rev. 2015 Feb 25;2:CD001939. [Epub ahead of print]

197.	Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy
	Zhu GQ1, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Aliment Pharmacol Ther. 2015 Feb 13. doi: 10.1111/apt.13122. [Epub ahead of print]

198.	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study
	Cárdenas A, Solà E, Rodríguez E, Barreto R, Graupera I, Pavesi M, Saliba F, Welzel T, Martinez-Gonzalez J, Gustot T, Bernardi M, Arroyo V, Ginès P; CANONIC study investigators of the EASL-CLIF Consortium. Crit Care. 2014 Dec 13;18(6):700. [Epub ahead of print]

199.	Patients with manifest hepatic encephalopathy can reveal impaired thermal perception
	Brenner M1, Butz M, May ES, Kahlbrock N, Kircheis G, Häussinger D, Schnitzler A. Acta Neurol Scand. 2015 Jan 28. doi: 10.1111/ane.12376. [Epub ahead of print]

200.	Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view
	Nguyen DL1, Morgan T1. Hepatol Int. 2014 Sep 1;8(2):447-451.

201.	The mind and liver test: a new approach to the diagnosis of minimal hepatic encephalopathy in resource-poor settings
	Das S1, Ali SM1, Seward J2, Venkataraman J3. Int J Hepatol. 2014;2014:475021. doi: 10.1155/2014/475021. Epub 2014 Dec 8.

202.	PET and MR imaging of neuroinflammation in hepatic encephalopathy
	Su YY1, Yang GF, Lu GM, Wu S, Zhang LJ. Metab Brain Dis. 2014 Dec 17. [Epub ahead of print]

203.	Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience
	Mantry PS1, Mehta A2, Graydon R2. Transplant Proc. 2014 Dec;46(10):3481-6. doi: 10.1016/j.transproceed.2014.10.021.

204.	Is There a Role for Probiotics in Liver Disease?
	Lo RS, Austin AS, Freeman JG. ScientificWorldJournal. 2014;2014:874768. Epub 2014 Nov 11.

205.	Covert hepatic encephalopathy: Agreement and predictive validity of different indices
	Montagnese S, Balistreri E, Schiff S, De Rui M, Angeli P, Zanus G, Cillo U, Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P. World J Gastroenterol. 2014 Nov 14;20(42):15756-62. doi: 10.3748/wjg.v20.i42.15756.

206.	Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes
	Scott LJ. Drugs. 2014 Dec;74(18):2153-60. doi: 10.1007/s40265-014-0300-y.

207.	Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
	Bajaj JS1, Barrett AC, Bortey E, Paterson C, Forbes WP. Aliment Pharmacol Ther. 2014 Oct 22. doi: 10.1111/apt.12993. [Epub ahead of print]

208.	Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes
	Scott LJ. Drugs. 2014 Oct 29. [Epub ahead of print]

209.	Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
	Bajaj JS1, Barrett AC, Bortey E, Paterson C, Forbes WP. Aliment Pharmacol Ther. 2014 Oct 22. doi: 10.1111/apt.12993. [Epub ahead of print]

210.	FOUR Score, a Reliable Score for Assessing Overt Hepatic Encephalopathy in Cirrhotic Patients
	Mouri S1, Tripon S, Rudler M, Mallet M, Mayaux J, Thabut D, Weiss N. Neurocrit Care. 2014 Oct 21. [Epub ahead of print]

211.	MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
	Martel-Laferrière V1, Homberger C, Bichoupan K, Dieterich DT. BMC Gastroenterol. 2014 Oct 17;14(1):185. doi: 10.1186/1471-230X-14-185.

212.	THDP17 Decreases Ammonia Production through Glutaminase Inhibition. A New Drug for Hepatic Encephalopathy Therapy
	Díaz-Herrero MM1, Del Campo JA2, Carbonero-Aguilar P1, Vega-Pérez JM3, Iglesias-Guerra F3, Periñán I3, Miñano FJ4, Bautista J1, Romero-Gómez M2. PLoS One. 2014 Oct 17;9(10):e109787. doi: 10.1371/journal.pone.0109787. eCollection 2014.

213.	Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy- a non-inferiority randomized controlled trial
	Pratap Mouli V1, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, Joshi YK. Hepatol Res. 2014 Sep 29. doi: 10.1111/hepr.12429. [Epub ahead of print]

214.	Reestablishing brain networks in patients without overt hepatic encephalopathy after liver transplantation
	Lin WC1, Hsu TW2, Chen CL3, Lu CH4, Chen HL5, Cheng YF1, Lin CP6. J Cereb Blood Flow Metab. 2014 Sep 17. doi: 10.1038/jcbfm.2014.143. [Epub ahead of print]

215.	Management of Complications of End-Stage Liver Disease in the Intensive Care Unit
	DellaVolpe JD1, Garavaglia JM2, Huang DT3. J Intensive Care Med. 2014 Sep 15. pii: 0885066614551144. [Epub ahead of print]

216.	Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy
	Holecek M. Nutrition. 2014 Mar 30. pii: S0899-9007(14)00150-6. doi: 10.1016/j.nut.2014.03.016. [Epub ahead of print]

217.	Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute on chronic liver failure
	Romero-Gómez M1, Montagnese S2, Jalan R3. J Hepatol. 2014 Sep 9. pii: S0168-8278(14)00646-1. doi: 10.1016/j.jhep.2014.09.005. [Epub ahead of print]

218.	Non invasive blood flow measurement in cerebellum detects minimal hepatic encephalopathy earlier than psychometric tests
	Felipo V, Urios A, Giménez-Garzó C, Cauli O, Andrés-Costa MJ, González O, Serra MA, Sánchez-González J, Aliaga R, Giner-Durán R, Belloch V, Montoliu C. World J Gastroenterol. 2014 Sep 7;20(33):11815-25. doi: 10.3748/wjg.v20.i33.11815.

219.	Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization
	Patidar KR1, Thacker LR2, Wade JB3, Sterling RK1, Sanyal AJ1, Siddiqui MS1, Matherly SC1, Stravitz RT1, Puri P1, Luketic VA1, Fuchs M1, White MB1, Noble NA1, Unser AB1, Gilles H1, Heuman DM1, Bajaj JS1. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.264. [Epub ahead of print]

220.	Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy
	Savlan I1, Liakina V2, Valantinas J3. Medicina (Kaunas). 2014;50(2):75-81. doi: 10.1016/j.medici.2014.06.008. Epub 2014 Jun 27.

221.	Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
	Sharma K1, Pant S, Misra S, Dwivedi M, Misra A, Narang S, Tewari R, Bhadoria AS. Saudi J Gastroenterol. 2014 Jul-Aug;20(4):225-32. doi: 10.4103/1319-3767.136975.

222.	Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study
	Campagna F1, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P. Liver Int. 2014 Jul 9. doi: 10.1111/liv.12635. [Epub ahead of print]

223.	Disrupted small world networks in patients without overt hepatic encephalopathy: A resting state fMRI study
	Zhang LJ1, Zheng G2, Zhang L3, Zhong J4, Li Q3, Zhao TZ2, Lu GM5. Eur J Radiol. 2014 Jul 2. pii: S0720-048X(14)00337-4. doi: 10.1016/j.ejrad.2014.06.019. [Epub ahead of print]

224.	Brain oscillatory activity during sleep shows unknown dysfunctions in early encephalopathy
	Martino ME1, Fernández-Lorente J, Romero-Vives M, Bárcena R, Gaztelu JM. J Physiol Biochem. 2014 Jul 30. [Epub ahead of print]

225.	Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials
	Xu J1, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB. Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):354-60.

226.	Correction of Hyponatremia Improves Cognition, Quality of Life, and Brain Edema in Cirrhosis
	Ahluwalia V1, Heuman DM2, Feldman G3, Wade JB4, Thacker LR5, Gavis E2, Gilles H2, Unser A2, White MB2, Bajaj JS6. J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00537-6. doi: 10.1016/j.jhep.2014.07.033. [Epub ahead of print]

227.	Challenges in Diagnosing Hepatic Encephalopathy
	Weissenborn K. Neurochem Res. 2014 Aug 21. [Epub ahead of print]

228.	Validation of EncephalApp, Smartphone-based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.
	Bajaj JS1, Heuman DM2, Sterling RK2, Sanyal AJ2, Siddiqui M2, Matherly S2, Luketic V2, Stravitz RT2, Fuchs M2, Thacker LR3, Gilles H2, White MB2, Unser A2, Hovermale J2, Gavis E2, Noble NA2, Wade JB4.

229.	Hepatic encephalopathy: how to test and treat
	Rahimi RS1, Rockey DC. Curr Opin Gastroenterol. 2014 May;30(3):265-71. doi: 10.1097/MOG.0000000000000066.

230.	Brain magnetic resonance in hepatic encephalopathy
	Alonso J1, Córdoba J2, Rovira A3. Semin Ultrasound CT MR. 2014 Apr;35(2):136-52. doi: 10.1053/j.sult.2013.09.008.

231.	Sodium benzoate for treatment of hepatic encephalopathy
	Misel ML, Gish RG, Patton H, Mendler M. Gastroenterol Hepatol (N Y). 2013 Apr;9(4):219-27.

232.	Survival in infection-related acute-on-chronic liver failure is defined by extra-hepatic organ failures
	Bajaj JS1, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS; on behalf of NACSELD. Hepatology. 2014 Feb 20. doi: 10.1002/hep.27077. [Epub ahead of print]

233.	Cerebral Hemodynamics In Cirrhotic Patients With Hepatic Encephalopathy
	Macías-Rodríguez RU1, Duarte-Rojo A, Cantú-Brito C, Sauerbruch T, Ruiz-Margáin A, Trebicka J, Green-Gómez M, Díaz Ramírez JB, Sierra Beltrán M, Uribe-Esquivel M, Torre A. Liver Int. 2014 Apr 1. doi: 10.1111/liv.12557. [Epub ahead of print]

234.	Management of hyponatremia in clinical hepatology practice
	Kwo PY. Curr Gastroenterol Rep. 2014 May;16(5):382. doi: 10.1007/s11894-014-0382-4.

235.	Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: Systematic review
	Metcalfe EL1, Avenell A2, Fraser A3. Clin Nutr. 2014 Mar 6. pii: S0261-5614(14)00073-9. doi: 10.1016/j.clnu.2014.02.011. [Epub ahead of print]

236.	TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: An updated meta-analysis
	Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. World J Gastroenterol. 2014 Mar 14;20(10):2704-2714.

237.	Optimal treatment of hepatic encephalopathy
	Waghray A1, Waghray N, Kanna S, Mullen K. Minerva Gastroenterol Dietol. 2014 Mar;60(1):55-70.

238.	Treatment Options for Covert Hepatic Encephalopathy
	Waghray N1, Waghray A, Mullen K. Curr Treat Options Gastroenterol. 2014 Mar 13. [Epub ahead of print]

239.	Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests
	Berlioux P, Robic MA, Poirson H, Métivier S, Otal P, Barret C, Lopez F, Péron JM, Vinel JP, Bureau C. Hepatology. 2014 Feb;59(2):622-9.

240.	Asterixis: a study of 103 patients
	Pal G1, Lin MM, Laureno R. Metab Brain Dis. 2014 Mar 7. [Epub ahead of print]

241.	Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis
	Ahluwalia V1, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS. Metab Brain Dis. 2014 Mar 4. [Epub ahead of print]

242.	Does H. pylori Eradication Therapy Benefit Patients With Hepatic Encephalopathy?: Systematic Review
	Schulz C1, Schütte K, Malfertheiner P. J Clin Gastroenterol. 2014 Feb 27. [Epub ahead of print]

243.	Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy?
	Ahuja NK, Ally WA, Caldwell SH. Ann Hepatol. 2014 Mar-Apr;13(2):179-86.

244.

Bacterial Infections in Cirrhosis. A Position Statement based on the EASL Special Conference 2013

Jalan R1, Fernandez J2, Wiest R3, Schnabl B4, Moreau R5, Angeli P6, Stadlbauer V7, Thierry Gustot T8, Bernardi M9, Canton R10, Agustin Albillos A11, Lammert F12, Wilmer A13, Mookerjee R1, Vila J14, Garcia-Martinez R2, Wendon J15, Such J16, Cordoba J17, Sanyal A18, Garcia-Tsao G19, Arroyo V2, Burroughs A20, Ginès P21. J Hepatol. 2014 Feb 11. pii: S0168-8278(14)00097-X. doi: 10.1016/j.jhep.2014.01.024. [Epub ahead of print]

245.	Analgesia for the Cirrhotic Patient: A Literature Review and Recommendations
	Dwyer JP1, Jayasekera C, Nicoll A. J Gastroenterol Hepatol. 2014 Feb 18. doi: 10.1111/jgh.12560. [Epub ahead of print]

246.	Effects of hyperammonemia on brain energy metabolism: controversial findings in vivo and in vitro
	Schousboe A1, Waagepetersen HS, Leke R, Bak LK. Metab Brain Dis. 2014 Mar 1. [Epub ahead of print]

247.	Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy
	Mullen KD1, Sanyal AJ2, Bass NM3, Poordad FF4, Sheikh MY5, Frederick RT6, Bortey E7, Forbes WP7. Clin Gastroenterol Hepatol. 2013 Dec 21. pii: S1542-3565(13)01968-X. doi: 10.1016/j.cgh.2013.12.021. [Epub ahead of print]

248.	Role of Magnetic Resonance Elastography in compensated and decompensated liver disease
	Asrani SK1, Talwalkar JA2, Kamath PS3, Shah VH4, Saracino G5, Jennings L6, Gross JB7, Venkatesh S8, Ehman RL9. J Hepatol. 2013 Dec 19. pii: S0168-8278(13)00884-2. doi: 10.1016/j.jhep.2013.12.016. [Epub ahead of print]

249.	The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications
	Bajaj JS1, Heuman DM2, Hylemon PB3, Sanyal AJ2, White MB2, Monteith P2, Noble NA2, Unser AB2, Daita K3, Fisher AR4, Sikaroodi M4, Gillevet PM4. J Hepatol. 2013 Dec 24. pii: S0168-8278(13)00887-8. doi: 10.1016/j.jhep.2013.12.019. [Epub ahead of print]

250.	Diagnosis of Covert Hepatic Encephalopathy Without Specialized Tests
	Nabi E1, Thacker LR2, Wade JB3, Sterling RK1, Stravitz RT1, Fuchs M1, Heuman DM1, Bouneva I1, Sanyal AJ1, Siddiqui MS1, Luketic V1, White MB1, Monteith P1, Noble NA1, Unser A1, Bajaj JS4. Clin Gastroenterol Hepatol. 2013 Dec 19. pii: S1542-3565(13)01966-6. doi: 10.1016/j.cgh.2013.12.020. [Epub ahead of print]

251.	Useful tests for hepatic encephalopathy in clinical practice
	Nabi E, Bajaj JS. Curr Gastroenterol Rep. 2014 Jan;16(1):362. doi: 10.1007/s11894-013-0362-0.

252.	Microglial proliferation in the brain of chronic alcoholics with hepatic encephalopathy
	Dennis CV, Sheahan PJ, Graeber MB, Sheedy DL, Kril JJ, Sutherland GT. Metab Brain Dis. 2013 Dec 19. [Epub ahead of print]

253.	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
	Poynard T1, Vergniol J2, Ngo Y3, Foucher J2, Munteanu M3, Merrouche W2, Colombo M4, Thibault V5, Schiff E6, Brass CA7, Albrecht JK7, Rudler M8, Deckmyn O3, Lebray P8, Thabut D8, Ratziu V8, de Ledinghen V2; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00817-9. doi: 10.1016/j.jhep.2013.11.016. [Epub ahead of print]

254.	Management of End-stage Liver Disease
	Liou IW. Med Clin North Am. 2014 Jan;98(1):119-52. doi: 10.1016/j.mcna.2013.09.006. Epub 2013 Oct 30.

255.	Branched-chain amino acids in liver diseases
	Tajiri K, Shimizu Y. World J Gastroenterol. 2013 Nov 21;19(43):7620-9. doi: 10.3748/wjg.v19.i43.7620.

256.	Treatment of hyperammonemia in liver failure
	Jover-Cobos M, Khetan V, Jalan R. Curr Opin Clin Nutr Metab Care. 2014 Jan;17(1):105-10. doi: 10.1097/MCO.0000000000000012.

257.	Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation Outcomes
	Teperman LW. Int J Hepatol. 2013;2013:952828. Epub 2013 Nov13.

258.	Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy
	Jayakumar AR, Tong XY, Curtis KM, Ruiz-Cordero R, Abreu MT, Norenberg MD. J Neurochem. 2013 Nov 1. doi: 10.1111/jnc.12516. [Epub ahead of print]

259.	Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled Trial
	Lunia MK, Chander Sharma B, Sharma P, Sachdeva S, Srivastava S. Clin Gastroenterol Hepatol. 2013 Nov 15. pii: S1542-3565(13)01743-6. doi: 10.1016/j.cgh.2013.11.006. [Epub ahead of print]

260.	Recent insights into the pathogenesis of hepatic encephalopathy and treatments
	Sturgeon JP, Shawcross DL. Expert Rev Gastroenterol Hepatol. 2013 Nov 18. [Epub ahead of print]

261.	Diffusion-weighted imaging in acute hyperammonemic encephalopathy
	Rosario M, McMahon K, Finelli PF. Neurohospitalist. 2013 Jul;3(3):125-30. doi: 10.1177/1941874412467806.

262.	Persistent repeated measurements by Magnetic Resonance Spectroscopy demonstrate Minimal Hepatic Encephalopathy: a case report
	Scheau C, Popa G, Ghergus A, Preda E, Capsa R, Lupescu I. J Med Life. 2013 Sep 15;6(3):299-301. Epub 2013 Sep 25.

263.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, Schulze A, Longo N, Bartley J, Berquist W, Gallagher R, Smith W, McCandless SE, Harding C, Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Dickinson K, Moors T, Norris C, Coakley D, Milikien DA, Nagamani SC, Lemons C, Lee B, Scharschmidt BF. Mol Genet Metab. 2013 Oct 8. pii: S1096-7192(13)00329-6. doi: 10.1016/j.ymgme.2013.09.017. [Epub ahead of print]

264.	A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy
	Wang QM, Ji Q, Duan ZJ, Zhang M, Chang QY.

265.	Hepatic encephalopathy: effects of liver failure on brain function
	Felipo V. Nat Rev Neurosci. 2013 Oct 23. doi: 10.1038/nrn3587. [Epub ahead of print]

266.	Oral glutamine challenge improves the performance of psychometric tests for the diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis
	Irimia R, Stanciu C, Cojocariu C, Sfarti C, Trifan A. J Gastrointestin Liver Dis. 2013 Sep;22(3):277-81.

267.	Pathophysiology of Encephalopathy and Delirium
	Williams ST. J Clin Neurophysiol. 2013 Oct;30(5):435-437.

268.	Insight into the relationship between brain/behavioral speed and variability in patients with minimal hepatic encephalopathy
	Schiff S, D'Avanzo C, Cona G, Goljahani A, Montagnese S, Volpato C, Gatta A, Sparacino G, Amodio P, Bisiacchi P. Clin Neurophysiol. 2013 Sep 10. pii: S1388-2457(13)00983-8. doi: 10.1016/j.clinph.2013.08.004. [Epub ahead of print]

269.	Clinical and radiological impact of liver transplantation for brain in cirrhosis patients without hepatic encephalopathy
	Ishihara T, Ito M, Niimi Y, Tsujimoto M, Senda J, Kawai Y, Watanabe H, Ishigami M, Ito T, Kamei H, Onishi Y, Nakamura T, Goto H, Naganawa S, Kiuchi T, Sobue G. Clin Neurol Neurosurg. 2013 Sep 10. pii: S0303-8467(13)00318-1. doi: 10.1016/j.clineuro.2013.08.015. [Epub ahead of print]

270.	Roles of Changes in Active Glutamine Transport in Brain Edema Development During Hepatic Encephalopathy: An Emerging Concept
	Zielinska M, Popek M, Albrecht J. Neurochem Res. 2013 Sep 26. [Epub ahead of print]

271.	Prevalence of Minimal Hepatic Encephalopathy and Quality of Life in Patients with Decompensated Cirrhosis
	Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Hepatol Res. 2013 Aug 19. doi: 10.1111/hepr.12227. [Epub ahead of print]

272.	Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: a randomized, double blind placebo-controlled trial
	Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R, Fernandes LN. Hepatol Res. 2013 Sep 3. doi: 10.1111/hepr.12235. [Epub ahead of print]

273.	In patients with liver cirrhosis, proinflammatory interleukins correlate with health-related quality of life irrespective of minimal hepatic encephalopathy
	Wunsch E, Koziarska D, Milkiewicz M, Naprawa G, Nowacki P, Hartleb M, Milkiewicz P. Eur J Gastroenterol Hepatol. 2013 Sep 9. [Epub ahead of print]

274.	Image-guided Intervention in Management of Complications of Portal Hypertension: More than TIPS for Success
	Kirby JM, Cho KJ, Midia M. Radiographics. 2013 Sep;33(5):1473-96. doi: 10.1148/rg.335125166.

275.	Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine
	Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH. Ann Hepatol. 2013 Sep-Oct;12(5):803-9.

276.	Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives
	Holecek M. Metab Brain Dis. 2013 Aug 31. [Epub ahead of print]

277.	Evolving Concepts: The Negative Effect of Minimal Hepatic Encephalopathy and Role for Prophylaxis in Patients With Cirrhosis
	Prakash RK, Kanna S, Mullen KD. Clin Ther. 2013 Aug 22. pii: S0149-2918(13)00811-4. doi: 10.1016/j.clinthera.2013.07.421. [Epub ahead of print]

278.	Update on management of patients with overt hepatic encephalopathy
	Chacko KR, Sigal SH. Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068.

279.	The thalamus in cirrhotic patients with and without hepatic encephalopathy: A volumetric MRI study
	Tao R, Zhang J, You Z, Wei L, Fan Y, Cui J, Wang J. Eur J Radiol. 2013 Aug 15. pii: S0720-048X(13)00404-X. doi: 10.1016/j.ejrad.2013.07.029. [Epub ahead of print]

280.	Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China
	Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. World J Gastroenterol. 2013 Aug 14;19(30):4984-91. doi: 10.3748/wjg.v19.i30.4984.

281.	Effects of Oral Branched-Chain Amino Acids on Hepatic Encephalopathy and Outcome in Patients With Liver Cirrhosis
	Kawaguchi T, Taniguchi E, Sata M. Nutr Clin Pract. 2013 Aug 14. [Epub ahead of print]

282.	Rifaximin-mediated changes to the epithelial cell proteome: 2-d gel analysis
	Schrodt C, McHugh EE, Gawinowicz MA, Dupont HL, Brown EL. PLoS One. 2013 Jul 26;8(7):e68550. doi: 10.1371/journal.pone.0068550. Print 2013.

283.	Rehabilitation for cirrhotic patients discharged after hepatic encephalopathy improves survival
	Andersen MM, Aunt S, Jensen NM, Homann C, Manniche J, Svendsen S, Christensen E, Reher-Langberg A, Schiødt FV. Dan Med J. 2013 Aug;60(8):A4683.

284.	Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy
	Rivera-Espinosa L, Floriano-Sánchez E, Pedraza-Chaverrí J, Coballase-Urrutia E, Sampieri AI, Ortega-Cuellar D, Cárdenas-Rodríguez N, Carmona-Aparicio L. Int J Mol Sci. 2013 Aug 5;14(8):16184-206. doi: 10.3390/ijms140816184.

285.	A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
	Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. Am J Gastroenterol. 2013 Jul 23. doi: 10.1038/ajg.2013.219. [Epub ahead of print]

286.	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study
	Simón-Talero M, García-Martínez R, Torrens M, Augustin S, Gómez S, Pereira G, Guevara M, Ginés P, Soriano G, Román E, Sánchez-Delgado J, Ferrer R, Nieto JC, Sunyé P, Fuentes I, Esteban R, Córdoba J. J Hepatol. 2013 Jul 18. pii: S0168-8278(13)00531-X. doi: 10.1016/j.jhep.2013.07.020. [Epub ahead of print]

287.	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
	Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group. Hepatology. 2013 Jul 11. doi: 10.1002/hep.26611. [Epub ahead of print]

288.	Cerebral blood flow measured by arterial-spin labeling MRI: A useful biomarker for characterization of minimal hepatic encephalopathy in patients with cirrhosis
	Zheng G, Zhang LJ, Zhong J, Wang Z, Qi R, Shi D, Lu GM. Eur J Radiol. 2013 Jul 9. pii: S0720-048X(13)00295-7. doi: 10.1016/j.ejrad.2013.06.002. [Epub ahead of print]

289.	Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy
	Joshi D, O'Grady J, Patel A, Shawcross D, Connor S, Deasy N, Willars C, Bernal W, Wendon J, Auzinger G. Liver Int. 2013 Jun 20. doi: 10.1111/liv.12257. [Epub ahead of print]

290.	Grey and white matter abnormalities in minimal hepatic encephalopathy: a study combining voxel-based morphometry and tract-based spatial statistics
	Qi R, Zhang LJ, Zhong J, Zhu T, Zhang Z, Xu C, Zheng G, Lu GM. Eur Radiol. 2013 Jul 10. [Epub ahead of print]

291.	Association of Helicobacter pylori infection with hepatic encephalopathy risk: A systematic review
	Hu BL, Wang HY, Yang GY. Clin Res Hepatol Gastroenterol. 2013 Jul 2. pii: S2210-7401(13)00116-2. doi: 10.1016/j.clinre.2013.05.004. [Epub ahead of print]

292.	Abnormal baseline brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy revealed by resting-state functional MRI
	Lv XF, Ye M, Han LJ, Zhang XL, Cai PQ, Jiang GH, Qiu YW, Qiu SJ, Wu YP, Liu K, Liu ZY, Wu PH, Xie CM. Metab Brain Dis. 2013 Jul 9. [Epub ahead of print]

293.	Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study
	Koziarska D, Wunsch E, Milkiewicz M, Wójcicki M, Nowacki P, Milkiewicz P. BMC Gastroenterol. 2013 Jul 2;13:107. doi: 10.1186/1471-230X-13-107.

294.	The liver-brain axis in liver failure: neuroinflammation and encephalopathy
	Butterworth RF. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. doi: 10.1038/nrgastro.2013.99. [Epub ahead of print]

295.	Therapeutic effects of blood purification in treatment of fulminant hepatic failure
	Pu Y, Yang D, Mao Y, Zhang Y, Chen K. Braz J Infect Dis. 2013 Jun 26. pii: S1413-8670(13)00100-1. doi: 10.1016/j.bjid.2012.11.008. [Epub ahead of print]

296.	Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias
	Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, Dimmock D, Baumgart S. Mol Genet Metab. 2013 May 29. pii: S1096-7192(13)00180-7. doi: 10.1016/j.ymgme.2013.05.014. [Epub ahead of print]

297.	Acute Fulminant Hepatic Failure, Encephalopathy and Early CT Changes
	Thayapararajah SW, Gulka I, Al-Amri A, Das S, Young GB. Can J Neurol Sci. 2013 Jul;40(4):553-7.

298.	Synbiotic formulation of probiotic and lactulose combination for hepatic encephalopathy treatment: A realistic hope?
	Sekhar MS, Unnikrishnan MK, Rodrigues GS, Mukhopadhyay C. Med Hypotheses. 2013 Jun 8. pii: S0306-9877(13)00245-4. doi: 10.1016/j.mehy.2013.05.016. [Epub ahead of print]

299.	Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy
	Hung PC, Wang HS, Hsia SH, Wong AM. Brain Dev. 2013 Jun 15. pii: S0387-7604(13)00174-5. doi: 10.1016/j.braindev.2013.05.010. [Epub ahead of print]

300.	Percutaneous Transvenous Embolization for Portal-Systemic Shunts associated with Encephalopathy: Long-term outcomes in 14 patients
	Naeshiro N, Kakizawa H, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Ishikawa M, Awai K, Chayama K. Hepatol Res. 2013 Jun 7. doi: 10.1111/hepr.12181. [Epub ahead of print]

301.	Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients: An Open-label, Dose-escalating, Single-cohort Study
	Ventura-Cots M, Arranz JA, Simón-Talero M, Torrens M, Blanco A, Riudor E, Fuentes I, Suñé P, Soriano G, Córdoba J. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]

302.	Branched-chain amino acids and ammonia metabolism in liver disease: Therapeutic implications
	Holecek M. Nutrition. 2013 Jun 4. pii: S0899-9007(13)00090-7. doi: 10.1016/j.nut.2013.01.022. [Epub ahead of print]

303.	Sleep-wake abnormalities in patients with cirrhosis
	Montagnese S, De Pittà C, De Rui M, Corrias M, Turco M, Merkel C, Amodio P, Costa R, Skene DJ, Gatta A. Hepatology. 2013 Jun 6. doi: 10.1002/hep.26555. [Epub ahead of print]

304.	A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy
	Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. Nutr J. 2013 Jun 6;12(1):74. [Epub ahead of print]

305.	Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials
	Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Risum N, Vilstrup H. J Nutr. 2013 Jun 5. [Epub ahead of print]

306.	Precipitants of hepatic encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent manner
	Lachmann V, Görg B, Bidmon HJ, Keitel V, Häussinger D. Arch Biochem Biophys. 2013 May 24. pii: S0003-9861(13)00155-0. doi: 10.1016/j.abb.2013.05.004. [Epub ahead of print]

307.	Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy
	Felipo V, Urios A, Valero P, Sánchez M, Serra MA, Pareja I, Rodríguez F, Gimenez-Garzó C, Sanmartín J, Montoliu C. Liver Int. 2013 May 9. doi: 10.1111/liv.12206. [Epub ahead of print]

308.	Cognitive Dysfunction is Associated with Poor Socio-Economic Status in Patients with Cirrhosis: an International Multi-Center Study
	Bajaj JS, Riggio O, Allampati S, Prakash R, Gioia S, Onori E, Piazza N, Noble NA, White MB, Mullen KD. Clin Gastroenterol Hepatol. 2013 May 21. pii: S1542-3565(13)00689-7. doi: 10.1016/j.cgh.2013.05.010. [Epub ahead of print]

309.	Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis
	Irimia R, Trifan A. Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1021-7.

310.	Hepatic encephalopathy: etiology, pathogenesis, and clinical signs
	Salgado M, Cortes Y. Compend Contin Educ Vet. 2013;35(6):E1-9.

311.	Hepatic encephalopathy: diagnosis and treatment
	Salgado M, Cortes Y. Compend Contin Educ Vet. 2013;35(6):E1-E10.

312.	Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.
	Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Gastroenterol Res Pract. 2013;2013:236963. doi: 10.1155/2013/236963. Epub 2013 Apr 3.

313.	Role of the heme oxygenase/carbon monoxide pathway in the pathogenesis and prevention of hepatic encephalopathy
	Wang QM, Yin XY, Duan ZJ, Guo SB, Sun XY. Mol Med Rep. 2013 May 13. doi: 10.3892/mmr.2013.1472. [Epub ahead of print]

314.	Differential Impact of Hyponatremia and Hepatic Encephalopathy on Health-Related Quality of Life and Brain Metabolite Abnormalities in Cirrhosis
	Ahluwalia V, Wade JB, Thacker L, Kraft KA, Sterling RK, Stravitz RT, Fuchs M, Bouneva I, Puri P, Luketic V, Sanyal AJ, Gilles H, Heuman DM, Bajaj JS. J Hepatol. 2013 May 7. pii: S0168-8278(13)00278-X. doi: 10.1016/j.jhep.2013.04.023. [Epub ahead of print]

315.	Update on the management of cirrhosis - focus on cost-effective preventative strategies
	Neff GW, Kemmer N, Duncan C, Alsina A. Clinicoecon Outcomes Res. 2013 Apr 12;5:143-52. doi: 10.2147/CEOR.S30675. Print 2013.

316.	Use of ImPACT to Diagnose Minimal Hepatic Encephalopathy: An Accurate, Practical, User-Friendly Internet-Based Neuropsychological Test Battery
	Tsushima M, Tsushima W, Tsushima V, Lim N, Madrigal E, Jackson C, Mendler MH. Dig Dis Sci. 2013 Apr 27. [Epub ahead of print]

317.	Cognitive assessment of patients with minimal hepatic encephalopathy in Brazil
	Torres DS, Abrantes J, Brandão-Mello CE. Metab Brain Dis. 2013 Apr 28. [Epub ahead of print]

318.	Clinical impact of arterial ammonia levels in ICU patients with different liver diseases
	Drolz A, Jäger B, Wewalka M, Saxa R, Horvatits T, Roedl K, Perkmann T, Zauner C, Kramer L, Ferenci P, Fuhrmann V. Intensive Care Med. 2013 May 1. [Epub ahead of print]

319.	Correlation between serum magnesium levels and hepatic encephalopathy in immediate post liver transplantation period
	Lopes PJ, Mei MF, Guardia AC, Stucchi RS, Udo EY, Warwar MI, Boin IF. Transplant Proc. 2013 Apr;45(3):1122-5. doi: 10.1016/j.transproceed.2013.02.011.

320.	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: evaluation by near infrared spectroscopy
	Nakanishi H, Kurosaki M, Nakanishi K, Tsuchiya K, Noda T, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Itakura J, Anami K, Asahina Y, Enomoto N, Higuchi T, Izumi N. Hepatol Res. 2013 Apr 5. doi: 10.1111/hepr.12127. [Epub ahead of print]

321.	GABAergic transmission in hepatic encephalopathy
	Sergeeva OA. Arch Biochem Biophys. 2013 Apr 23. pii: S0003-9861(13)00118-5. doi: 10.1016/j.abb.2013.04.005. [Epub ahead of print]

322.	Inflammation and Hepatic Encephalopathy
	Coltart I, Tranah TH, Shawcross DL. Arch Biochem Biophys. 2013 Apr 10. pii: S0003-9861(13)00105-7. doi: 10.1016/j.abb.2013.03.016. [Epub ahead of print]

323.	Cognitive functions in patients with liver cirrhosis: A tendency to commit more memory errors
	Cie?ko-Michalska I, Wójcik J, Senderecka M, Wyczesany M, Binder M, Szewczyk J, Dziedzic T, S?owik A, Mach T. Med Sci Monit. 2013 Apr 19;19:283-288.

324.	Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis
	Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Metab Brain Dis. 2013 Mar 15. [Epub ahead of print]

325.	Increased risk of cognitive impairment in cirrhotic patients with bacterial infections
	Merli M, Lucidi C, Pentassuglio I, Giannelli V, Giusto M, Gregorio VD, Pasquale C, Nardelli S, Lattanzi B, Venditti M, Riggio O. J Hepatol. 2013 Mar 21. pii: S0168-8278(13)00190-6. doi: 10.1016/j.jhep.2013.03.012. [Epub ahead of print]

326.	Hepatic encephalopathy associated with cancer or anticancer therapy
	Willson KJ, Nott LM, Broadbridge VT, Price T. Gastrointest Cancer Res. 2013 Jan;6(1):11-6.

327.	Update on cerebral uptake of blood ammonia
	Sørensen M. Metab Brain Dis. 2013 Mar 13. [Epub ahead of print]

328.	Altered Mental Status in Cirrhosis: Etiologies and Outcomes
	Rahimi RS, Elliott AC, Rockey DC. J Investig Med. 2013 Mar 7. [Epub ahead of print]

329.	Gut microbiota and hepatic encephalopathy
	Dhiman RK. Metab Brain Dis. 2013 Mar 6. [Epub ahead of print]

330.	Lactulose Is Highly Potential in Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: Results of a Controlled Randomized Trial
	Wen J, Liu Q, Song J, Tong M, Peng L, Liang H. Digestion. 2013 Mar 6;87(2):132-138. [Epub ahead of print]

331.	Neurotransmitter receptor alterations in hepatic encephalopathy: A review
	Palomero-Gallagher N, Zilles K. Arch Biochem Biophys. 2013 Mar 1. pii: S0003-9861(13)00061-1. doi: 10.1016/j.abb.2013.02.010. [Epub ahead of print]

332.	End-stage liver disease complications
	Rahimi RS, Rockey DC. Curr Opin Gastroenterol. 2013 Feb 19. [Epub ahead of print]

333.	The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy
	Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC. Epidemiol Infect. 2013 Feb 22:1-8. [Epub ahead of print]

334.	Effect of obstructive sleep apnea on the sleep architecture in cirrhosis
	Kappus MR, Leszczyszyn DJ, Moses L, Raman S, Heuman DM, Bajaj JS. J Clin Sleep Med. 2013 Mar 15;9(3):247-51. doi: 10.5664/jcsm.2488.

335.	Gastric Varices and Hepatic Encephalopathy: Treatment with Vascular Plug and Gelatin Sponge-assisted Retrograde Transvenous Obliteration--A Primary Report
	Gwon DI, Ko GY, Yoon HK, Sung KB, Kim JH, Shin JH, Ko HK, Song HY. Radiology. 2013 Mar 12. [Epub ahead of print]

336.	L-ornithine-L-aspartate for Hepatic Encephalopathy in Patients with Cirrhosis: A Meta-analysis of Randomized Controlled Trials
	Bai M, Yang Z, Qi X, Fan D, Han G. J Gastroenterol Hepatol. 2013 Feb 21. doi: 10.1111/jgh.12142. [Epub ahead of print]

337.	Serum Endotoxin, Inflammatory mediators and Magnetic Resonance Spectroscopy before and after treatment in patients with Minimal Hepatic Encephalopathy
	Jain L, Sharma BC, Srivastava S, Puri SK, Sharma P, Sarin S. J Gastroenterol Hepatol. 2013 Feb 21. doi: 10.1111/jgh.12160. [Epub ahead of print]

338.	Modulation of neural activation following treatment of hepatic encephalopathy
	McPhail MJ, Leech R, Grover VP, Fitzpatrick JA, Dhanjal NS, Crossey MM, Pflugrad H, Saxby BK, Wesnes K, Dresner MA, Waldman AD, Thomas HC, Taylor-Robinson SD. Neurology. 2013 Feb 20. [Epub ahead of print]

339.	Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy : A multi-center survey on safety & efficacy
	Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, Villalba J, Garcia-Pagan JC, Barrufet M, Jalan R, Brookes J, Thalassinos E, Burroughs AK, Cordoba J, Nevens F; on behalf of the EASL-CLIF-consortium. Hepatology. 2013 Feb 7. doi: 10.1002/hep.26314. [Epub ahead of print]

340.	The stroop smartphone APP is a short and valid method toscreen for minimal hepatic encephalopathy
	Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, Puri P, Siddiqui MS, Stravitz RT, Bouneva I, Luketic V, Noble N, White MB, Monteith P, Unser A, Wade JB. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26309. [Epub ahead of print]

341.	Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
	Brandi G, de Rosa F, Calzà L, Girolamo SD, Tufoni M, Ricci CS, Cirignotta F, Caraceni P, Biasco G. Liver Int. 2013 Mar;33(3):488-93. doi: 10.1111/liv.12102.

342.	Antibiotics for the treatment of hepatic encephalopathy
	Patidar KR, Bajaj JS. Metab Brain Dis. 2013 Feb 8. [Epub ahead of print]

343.	Acetyl-L-carnitine in hepatic encephalopathy
	Malaguarnera M. Metab Brain Dis. 2013 Feb 8. [Epub ahead of print]

344.	Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy
	Bak LK, Waagepetersen HS, Sørensen M, Ott P, Vilstrup H, Keiding S, Schousboe A. Metab Brain Dis. 2013 Jan 31. [Epub ahead of print]

345.	Altered effective connectivity network of the Basal Ganglia in low-grade hepatic encephalopathy: a resting-state FMRI study with granger causality analysis
	Qi R, Zhang LJ, Zhong J, Zhang Z, Ni L, Jiao Q, Liao W, Zheng G, Lu G. PLoS One. 2013;8(1):e53677. doi: 10.1371/journal.pone.0053677. Epub 2013 Jan 11

346.	Melatonin levels in serum and ascitic fluid of patients with hepatic encephalopathy
	Chojnacki C, Romanowski M, Winczyk K, B?asiak J, Chojnacki J. Gastroenterol Res Pract. 2012;2012:510764. doi: 10.1155/2012/510764. Epub 2012 Dec 30.

347.	Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy
	Görg B, Bidmon HJ, Häussinger D. Hepatology. 2013 Jan 16. doi: 10.1002/hep.26265. [Epub ahead of print]

348.	Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study
	Romeiro FG, da Silva Yamashiro F, Américo MF, Corá LA, Silva GF, Miranda J, Caramori CA. BMC Gastroenterol. 2013 Jan 16;13:13. doi: 10.1186/1471-230X-13-13.

349.	Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy
	Cicho?-Lach H, Michalak A. World J Gastroenterol. 2013 Jan 7;19(1):26-34. doi: 10.3748/wjg.v19.i1.26.

350.	Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy: A Retrospective Analysis
	Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N. J Clin Gastroenterol. 2013 Feb;47(2):188-92. doi: 10.1097/MCG.0b013e318276be13.

351.	Pathogenesis of hepatic encephalopathy
	Cie?ko-Michalska I, Szczepanek M, S?owik A, Mach T. Gastroenterol Res Pract. 2012;2012:642108. doi: 10.1155/2012/642108. Epub 2012 Dec 17.

352.	Disrupted Functional Connectivity of the Anterior Cingulate Cortex in Cirrhotic Patients without Overt Hepatic Encephalopathy: A Resting State fMRI Study
	Zhang LJ, Qi R, Zhong J, Ni L, Zheng G, Xu J, Lu GM. PLoS One. 2013;8(1):e53206. doi: 10.1371/journal.pone.0053206. Epub 2013 Jan 7.

353.	Clinical Manifestations and Treatment Options in Patients with Cirrhosis and Diabetes Mellitus
	Gundling F, Seidl H, Strassen I, Haller B, Siegmund T, Umgelter A, Pehl C, Schepp W, Schumm-Draeger PM. Digestion. 2013 Jan 10;87(2):75-84. [Epub ahead of print]

354.	The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy.
	Metab Brain Dis. 2013 Jan 10. [Epub ahead of print] Lauridsen MM, Thiele M, Kimer N, Vilstrup H.

355.	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
	Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Metab Brain Dis. 2012 Dec 29. [Epub ahead of print]

356.	Glutamine in the Pathogenesis of Hepatic Encephalopathy: The Trojan Horse Hypothesis Revisited
	Rama Rao KV, Norenberg MD. Neurochem Res. 2013 Jan 1. [Epub ahead of print]

357.	Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates
	Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, Afshar K, Rümke S, Barg-Hock H, Strassburg CP, Hecker H, Tryc AB. Gut. 2013 Jan 7. [Epub ahead of print]

358.	Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients
	Nardelli S, Pentassuglio I, Pasquale C, Ridola L, Moscucci F, Merli M, Mina C, Marianetti M, Fratino M, Izzo C, Merkel C, Riggio O. Metab Brain Dis. 2013 Jan 8. [Epub ahead of print]

359.	How to diagnose hepatic encephalopathy in the emergency department
	Gundling F, Zelihic E, Seidl H, Haller B, Umgelter A, Schepp W, Dodt C. Ann Hepatol. 2013 Jan;12(1):108-14.

360.	Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy
	Torlot FJ, McPhail MJ, Taylor-Robinson SD. Aliment Pharmacol Ther. 2013 Jan 7. doi: 10.1111/apt.12199. [Epub ahead of print]

361.	Resting State Cortical Electroencephalographic Rhythms in Covert Hepatic Encephalopathy and Alzheimer's Disease
	Babiloni C, Vecchio F, Del Percio C, Montagnese S, Schiff S, Lizio R, Chini G, Serviddio G, Marzano N, Soricelli A, Frisoni GB, Rossini PM, Amodio P. J Alzheimers Dis. 2012 Dec 27. [Epub ahead of print]

362.	Increased Incidence of Orthopedic Fractures in Cirrhotic Patients: A Nationwide Population-Based Study
	Tsai CF, Liu CJ, Chen TJ, Chu CJ, Lin HC, Lee FY, Su TP, Lu CL. J Hepatol. 2012 Dec 10. pii: S0168-8278(12)00919-1. doi: 10.1016/j.jhep.2012.12.001. [Epub ahead of print]

363.	Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota
	Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. World J Gastroenterol. 2012 Dec 14;18(46):6693-700. doi: 10.3748/wjg.v18.i46.6693.

364.	Changes in expression of the chloride homeostasis-regulating genes, KCC2 and NKCC1, in the blood of cirrhotic patients with hepatic encephalopathy
	Li JJ, Ji R, Shi YQ, Wang YY, Yang YL, Dou KF. Exp Ther Med. 2012 Dec;4(6):1075-1080. Epub 2012 Sep 24.

365.	Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study
	Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O. Metab Brain Dis. 2012 Dec 7. [Epub ahead of print]

HEPATITIS

HCC

HRS

NASH

PBC

THROMBOCYTOPENIA

About CLDF

Board of Advisors/Faculty

2019 GI Fellow Board of Advisors

Other Resources

Liver News Library

Journal Abstracts

Hep C Link to Care

Centers of
Educational Expertise

Hepatology

Substance Use Disorder

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.